Abstract

Research Article

Psychosis in Parkinson’s Disease and Current Management Trends- an Updated Review of Literature

Rajib Dutta*

Published: 26 July, 2023 | Volume 7 - Issue 2 | Pages: 027057

As a neurodegenerative disorder, Parkinson’s disease (PD) is characterized by a combination of premotor, motor, and nonmotor symptoms. PD is commonly accompanied by psychosis, which is one of the commonest symptoms in the long run. As a result of Parkinson’s disease psychosis (PDP), symptoms can range from minor consequences of the disease (illusions, passage hallucinations, and presence hallucinations), to visual and nonvisual hallucinations and delusions. PDP is associated with a reduction in function and a reduction in quality of life as well. It is commonly believed that PDP is related to economic burden, and it has a significant impact on the utilization of long-term care services. The main focus should be on diagnosing, classifying, and managing PDP in an appropriate manner. As a first step in the management of PDP patients, the emphasis should be on identifying and treating any contributing medical factors, reducing or discontinuing medications that could cause or worsen psychosis, as well as nonpharmacological strategies and considering acetylcholinesterase inhibitors for treatment when dementia is present. A number of medications are being considered for use in PDP, including pimavanserin, quetiapine, and clozapine. The purpose of the current review is to provide a comprehensive understanding of the disorder in the general population with PD, including epidemiology, psychotic symptoms, risk factors, triggers, neuro-signaling pathways, diagnosis, and treatment of PDP.

Read Full Article HTML DOI: 10.29328/journal.jnnd.1001078 Cite this Article Read Full Article PDF

Keywords:

Parkinson’s disease; Parkinson’s disease psychosis; Diagnosis; Management; Pharmacological; Non-pharmacological

References

  1. Zaman V, Shields DC, Shams R, Drasites KP, Matzelle D, Haque A, Banik NL. Cellular and molecular pathophysiology in the progression of Parkinson's disease. Metab Brain Dis. 2021 Jun;36(5):815-827. doi: 10.1007/s11011-021-00689-5. Epub 2021 Feb 18. PMID: 33599945; PMCID: PMC8170715.
  2. Chaudhuri KR, Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P, Brown RG, Koller W, Barone P, MacPhee G, Kelly L, Rabey M, MacMahon D, Thomas S, Ondo W, Rye D, Forbes A, Tluk S, Dhawan V, Bowron A, Williams AJ, Olanow CW. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord. 2006 Jul;21(7):916-23. doi: 10.1002/mds.20844. PMID: 16547944.
  3. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003 Mar-Apr;24(2):197-211. doi: 10.1016/s0197-4580(02)00065-9. PMID: 12498954.
  4. Zesiewicz TA. Parkinson Disease. Continuum (Minneap Minn). 2019 Aug;25(4):896-918. doi: 10.1212/CON.0000000000000764. PMID: 31356286.
  5. Lee HM, Koh SB. Many Faces of Parkinson's Disease: Non-Motor Symptoms of Parkinson's Disease. J Mov Disord. 2015 May;8(2):92-7. doi: 10.14802/jmd.15003. Epub 2015 May 31. PMID: 26090081; PMCID: PMC4460545.
  6. Moustafa AA, Chakravarthy S, Phillips JR, Gupta A, Keri S, Polner B, Frank MJ, Jahanshahi M. Motor symptoms in Parkinson's disease: A unified framework. Neurosci Biobehav Rev. 2016 Sep;68:727-740. doi: 10.1016/j.neubiorev.2016.07.010. Epub 2016 Jul 12. PMID: 27422450.
  7. Witjas T, Kaphan E, Azulay JP, Blin O, Ceccaldi M, Pouget J, Poncet M, Chérif AA. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology. 2002 Aug 13;59(3):408-13. doi: 10.1212/wnl.59.3.408. PMID: 12177375.
  8. Frucht SJ. Parkinson disease: an update. Neurologist. 2004 Jul;10(4):185-94. doi: 10.1097/01.nrl.0000131146.08278.a5. PMID: 15245584; PMCID: PMC4119608.
  9. Tibar H, El Bayad K, Bouhouche A, Ait Ben Haddou EH, Benomar A, Yahyaoui M, Benazzouz A, Regragui W. Non-Motor Symptoms of Parkinson's Disease and Their Impact on Quality of Life in a Cohort of Moroccan Patients. Front Neurol. 2018 Apr 4;9:170. doi: 10.3389/fneur.2018.00170. PMID: 29670566; PMCID: PMC5893866.
  10. Bonnet AM, Jutras MF, Czernecki V, Corvol JC, Vidailhet M. Nonmotor symptoms in Parkinson's disease in 2012: relevant clinical aspects. Parkinsons Dis. 2012;2012:198316. doi: 10.1155/2012/198316. Epub 2012 Jul 25. PMID: 22888466; PMCID: PMC3410355.
  11. Zhang TM, Yu SY, Guo P, Du Y, Hu Y, Piao YS, Zuo LJ, Lian TH, Wang RD, Yu QJ, Jin Z, Zhang W. Nonmotor symptoms in patients with Parkinson disease: A cross-sectional observational study. Medicine (Baltimore). 2016 Dec;95(50):e5400. doi: 10.1097/MD.0000000000005400. PMID: 27977578; PMCID: PMC5268024.
  12. Ravan A, Ahmad FM, Chabria S, Gadhari M, Sankhla CS. Non-motor symptoms in an Indian cohort of Parkinson's disease patients and correlation of progression of non-motor symptoms with motor worsening. Neurol India. 2015 Mar-Apr;63(2):166-74. doi: 10.4103/0028-3886.156276. PMID: 25947979.
  13. Sauerbier A, Jitkritsadakul O, Titova N, Klingelhoefer L, Tsuboi Y, Carr H, Kumar H, Banerjee R, Erro R, Bhidayasiri R, Schrag A, Zis P, Lim SY, Al-Hashel JY, Kamel WA, Martinez-Martin P, Ray Chaudhuri K. Non-Motor Symptoms Assessed by Non-Motor Symptoms Questionnaire and Non-Motor Symptoms Scale in Parkinson's Disease in Selected Asian Populations. Neuroepidemiology. 2017;49(1-2):1-17. doi: 10.1159/000478702. Epub 2017 Aug 12. PMID: 28803229.
  14. Sung VW, Nicholas AP. Nonmotor symptoms in Parkinson's disease: expanding the view of Parkinson's disease beyond a pure motor, pure dopaminergic problem. Neurol Clin. 2013 Aug;31(3 Suppl):S1-16. doi: 10.1016/j.ncl.2013.04.013. Epub 2013 Jun 14. PMID: 23931951.
  15. Kalia LV, Kalia SK, Lang AE. Disease-modifying strategies for Parkinson's disease. Mov Disord. 2015 Sep 15;30(11):1442-50. doi: 10.1002/mds.26354. Epub 2015 Jul 24. PMID: 26208210.
  16. Stefanis L. α-Synuclein in Parkinson's disease. Cold Spring Harb Perspect Med. 2012 Feb;2(2):a009399. doi: 10.1101/cshperspect.a009399. PMID: 22355802; PMCID: PMC3281589.
  17. Luk KC, Kehm V, Carroll J, Zhang B, O'Brien P, Trojanowski JQ, Lee VM. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 2012 Nov 16;338(6109):949-53. doi: 10.1126/science.1227157. PMID: 23161999; PMCID: PMC3552321.
  18. Duffy MF, Collier TJ, Patterson JR, Kemp CJ, Fischer DL, Stoll AC, Sortwell CE. Quality Over Quantity: Advantages of Using Alpha-Synuclein Preformed Fibril Triggered Synucleinopathy to Model Idiopathic Parkinson's Disease. Front Neurosci. 2018 Sep 4;12:621. doi: 10.3389/fnins.2018.00621. PMID: 30233303; PMCID: PMC6132025.
  19. Jan A, Gonçalves NP, Vaegter CB, Jensen PH, Ferreira N. The Prion-Like Spreading of Alpha-Synuclein in Parkinson's Disease: Update on Models and Hypotheses. Int J Mol Sci. 2021 Aug 3;22(15):8338. doi: 10.3390/ijms22158338. PMID: 34361100; PMCID: PMC8347623.
  20. Meade RM, Fairlie DP, Mason JM. Alpha-synuclein structure and Parkinson's disease - lessons and emerging principles. Mol Neurodegener. 2019 Jul 22;14(1):29. doi: 10.1186/s13024-019-0329-1. PMID: 31331359; PMCID: PMC6647174.
  21. Statistics on Parkinson’s. Parkinson’s Disease Foundation website. www.pdf.org/en/parkinson_statistics. Accessed January 10, 2016.
  22. Nussbaum RL, Ellis CE. Alzheimer's disease and Parkinson's disease. N Engl J Med. 2003 Apr 3;348(14):1356-64. doi: 10.1056/NEJM2003ra020003. Erratum in: N Engl J Med. 2003 Jun 19;348(25):2588. PMID: 12672864.
  23. Lebouvier T, Chaumette T, Paillusson S, Duyckaerts C, Bruley des Varannes S, Neunlist M, Derkinderen P. The second brain and Parkinson's disease. Eur J Neurosci. 2009 Sep;30(5):735-41. doi: 10.1111/j.1460-9568.2009.06873.x. Epub 2009 Aug 27. PMID: 19712093.
  24. Ball N, Teo WP, Chandra S, Chapman J. Parkinson's Disease and the Environment. Front Neurol. 2019 Mar 19;10:218. doi: 10.3389/fneur.2019.00218. PMID: 30941085; PMCID: PMC6433887.
  25. Gallagher DA, Schapira AH. Etiopathogenesis and treatment of Parkinson's disease. Curr Top Med Chem. 2009;9(10):860-8. PMID: 19754402.
  26. Jankovic J, Tan EK. Parkinson's disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry. 2020 Aug;91(8):795-808. doi: 10.1136/jnnp-2019-322338. Epub 2020 Jun 23. PMID: 32576618.
  27. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol. 2006 Jun;5(6):525-35. doi: 10.1016/S1474-4422(06)70471-9. PMID: 16713924.
  28. de Rijk MC, Breteler MM, Graveland GA, Ott A, Grobbee DE, van der Meché FG, Hofman A. Prevalence of Parkinson's disease in the elderly: the Rotterdam Study. Neurology. 1995 Dec;45(12):2143-6. doi: 10.1212/wnl.45.12.2143. PMID: 8848182.
  29. Tysnes OB, Storstein A. Epidemiology of Parkinson's disease. J Neural Transm (Vienna). 2017 Aug;124(8):901-905. doi: 10.1007/s00702-017-1686-y. Epub 2017 Feb 1. PMID: 28150045.
  30. Simon DK, Tanner CM, Brundin P. Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology. Clin Geriatr Med. 2020 Feb;36(1):1-12. doi: 10.1016/j.cger.2019.08.002. Epub 2019 Aug 24. PMID: 31733690; PMCID: PMC6905381.
  31. Gillies GE, Pienaar IS, Vohra S, Qamhawi Z. Sex differences in Parkinson's disease. Front Neuroendocrinol. 2014 Aug;35(3):370-84. doi: 10.1016/j.yfrne.2014.02.002. Epub 2014 Mar 4. PMID: 24607323; PMCID: PMC4096384.
  32. Haaxma CA, Bloem BR, Borm GF, Oyen WJ, Leenders KL, Eshuis S, Booij J, Dluzen DE, Horstink MW. Gender differences in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2007 Aug;78(8):819-24. doi: 10.1136/jnnp.2006.103788. Epub 2006 Nov 10. PMID: 17098842; PMCID: PMC2117736.
  33. Cerri S, Mus L, Blandini F. Parkinson's Disease in Women and Men: What's the Difference? J Parkinsons Dis. 2019;9(3):501-515. doi: 10.3233/JPD-191683. PMID: 31282427; PMCID: PMC6700650.
  34. Moisan F, Kab S, Mohamed F, Canonico M, Le Guern M, Quintin C, Carcaillon L, Nicolau J, Duport N, Singh-Manoux A, Boussac-Zarebska M, Elbaz A. Parkinson disease male-to-female ratios increase with age: French nationwide study and meta-analysis. J Neurol Neurosurg Psychiatry. 2016 Sep;87(9):952-7. doi: 10.1136/jnnp-2015-312283. Epub 2015 Dec 23. PMID: 26701996; PMCID: PMC5013115.
  35. Wooten GF, Currie LJ, Bovbjerg VE, Lee JK, Patrie J. Are men at greater risk for Parkinson's disease than women? J Neurol Neurosurg Psychiatry. 2004 Apr;75(4):637-9. doi: 10.1136/jnnp.2003.020982. PMID: 15026515; PMCID: PMC1739032.
  36. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina BM, Schifitto G, Siderowf A, Tanner CM. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007 Jan 30;68(5):384-6. doi: 10.1212/01.wnl.0000247740.47667.03. Epub 2006 Nov 2. PMID: 17082464.
  37. Ou Z, Pan J, Tang S, Duan D, Yu D, Nong H, Wang Z. Global Trends in the Incidence, Prevalence, and Years Lived With Disability of Parkinson's Disease in 204 Countries/Territories From 1990 to 2019. Front Public Health. 2021 Dec 7;9:776847. doi: 10.3389/fpubh.2021.776847. PMID: 34950630; PMCID: PMC8688697.
  38. Dorsey ER, Sherer T, Okun MS, Bloem BR. The Emerging Evidence of the Parkinson Pandemic. J Parkinsons Dis. 2018;8(s1):S3-S8. doi: 10.3233/JPD-181474. PMID: 30584159; PMCID: PMC6311367.
  39. GBD 2016 Parkinson's Disease Collaborators. Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018 Nov;17(11):939-953. doi: 10.1016/S1474-4422(18)30295-3. Epub 2018 Oct 1. Erratum in: Lancet Neurol. 2021 Dec;20(12):e7. PMID: 30287051; PMCID: PMC6191528.
  40. Marras C, Beck JC, Bower JH, Roberts E, Ritz B, Ross GW, Abbott RD, Savica R, Van Den Eeden SK, Willis AW, Tanner CM; Parkinson’s Foundation P4 Group. Prevalence of Parkinson's disease across North America. NPJ Parkinsons Dis. 2018 Jul 10;4:21. doi: 10.1038/s41531-018-0058-0. PMID: 30003140; PMCID: PMC6039505.
  41. Orozco JL, Valderrama-Chaparro JA, Pinilla-Monsalve GD, Molina-Echeverry MI, Pérez Castaño AM, Ariza-Araújo Y, Prada SI, Takeuchi Y. Parkinson's disease prevalence, age distribution and staging in Colombia. Neurol Int. 2020 Jul 10;12(1):8401. doi: 10.4081/ni.2020.8401. PMID: 32774822; PMCID: PMC7378539.
  42. Hirsch L, Jette N, Frolkis A, Steeves T, Pringsheim T. The Incidence of Parkinson's Disease: A Systematic Review and Meta-Analysis. Neuroepidemiology. 2016;46(4):292-300. doi: 10.1159/000445751. Epub 2016 Apr 23. PMID: 27105081.
  43. Ma CL, Su L, Xie JJ, Long JX, Wu P, Gu L. The prevalence and incidence of Parkinson's disease in China: a systematic review and meta-analysis. J Neural Transm (Vienna). 2014 Feb;121(2):123-34. doi: 10.1007/s00702-013-1092-z. Epub 2013 Sep 22. PMID: 24057652.
  44. Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, Nelson LM. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol. 2003 Jun 1;157(11):1015-22. doi: 10.1093/aje/kwg068. PMID: 12777365.
  45. Rocca WA. The burden of Parkinson's disease: a worldwide perspective. Lancet Neurol. 2018 Nov;17(11):928-929. doi: 10.1016/S1474-4422(18)30355-7. Epub 2018 Oct 1. PMID: 30287052.
  46. Rizek P, Kumar N, Jog MS. An update on the diagnosis and treatment of Parkinson disease. CMAJ. 2016 Nov 1;188(16):1157-1165. doi: 10.1503/cmaj.151179. Epub 2016 May 24. PMID: 27221269; PMCID: PMC5088077.
  47. DeMaagd G, Philip A. Parkinson's Disease and Its Management: Part 1: Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and Diagnosis. P T. 2015 Aug;40(8):504-32. PMID: 26236139; PMCID: PMC4517533.
  48. Driver JA, Logroscino G, Gaziano JM, Kurth T. Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology. 2009 Feb 3;72(5):432-8. doi: 10.1212/01.wnl.0000341769.50075.bb. PMID: 19188574; PMCID: PMC2676726.
  49. Frei K, Truong DD. Hallucinations and the spectrum of psychosis in Parkinson's disease. J Neurol Sci. 2017 Mar 15;374:56-62. doi: 10.1016/j.jns.2017.01.014. Epub 2017 Jan 5. PMID: 28108020.
  50. Samudra N, Patel N, Womack KB, Khemani P, Chitnis S. Psychosis in Parkinson Disease: A Review of Etiology, Phenomenology, and Management. Drugs Aging. 2016 Dec;33(12):855-863. doi: 10.1007/s40266-016-0416-8. PMID: 27830568; PMCID: PMC6760850.
  51. Chendo I, Fabbri M, Godinho C, Moiron Simões R, Severiano Sousa C, Coelho M, Voon V, Ferreira JJ. High frequency of psychosis in late-stage Parkinsońs disease. Clin Park Relat Disord. 2021 Nov 24;5:100119. doi: 10.1016/j.prdoa.2021.100119. PMID: 34988427; PMCID: PMC8710406.
  52. Hely MA, Morris JG, Reid WG, Trafficante R. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord. 2005 Feb;20(2):190-9. doi: 10.1002/mds.20324. PMID: 15551331.
  53. Ravina B, Marder K, Fernandez HH, Friedman JH, McDonald W, Murphy D, Aarsland D, Babcock D, Cummings J, Endicott J, Factor S, Galpern W, Lees A, Marsh L, Stacy M, Gwinn-Hardy K, Voon V, Goetz C. Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Mov Disord. 2007 Jun 15;22(8):1061-8. doi: 10.1002/mds.21382. PMID: 17266092.
  54. Garofalo S, Justicia A, Arrondo G, Ermakova AO, Ramachandra P, Tudor-Sfetea C, Robbins TW, Barker RA, Fletcher PC, Murray GK. Cortical and Striatal Reward Processing in Parkinson's Disease Psychosis. Front Neurol. 2017 Apr 24;8:156. doi: 10.3389/fneur.2017.00156. PMID: 28484422; PMCID: PMC5402044.
  55. Toh WL, Yolland C, Gurvich C, Barnes J, Rossell SL. Non-visual hallucinations in Parkinson's disease: a systematic review. J Neurol. 2023 Jun;270(6):2857-2889. doi: 10.1007/s00415-022-11545-6. Epub 2023 Jan 27. PMID: 36702960; PMCID: PMC10188425.
  56. Goetz CG, Stebbins GT, Ouyang B. Visual plus nonvisual hallucinations in Parkinson's disease: development and evolution over 10 years. Mov Disord. 2011 Oct;26(12):2196-200. doi: 10.1002/mds.23835. Epub 2011 Jul 13. PMID: 21755536.
  57. Goldman JG, Vaughan CL, Goetz CG. An update expert opinion on management and research strategies in Parkinson's disease psychosis. Expert Opin Pharmacother. 2011 Sep;12(13):2009-24. doi: 10.1517/14656566.2011.587122. Epub 2011 Jun 2. PMID: 21635198; PMCID: PMC3152685.
  58. Weil RS, Reeves S. Hallucinations in Parkinson's disease: new insights into mechanisms and treatments. Adv Clin Neurosci Rehabil. 2020 Jul 13;19(4):ONNS5189. doi: 10.47795/ONNS5189. PMID: 33102741; PMCID: PMC7116251.
  59. Forsaa EB, Larsen JP, Wentzel-Larsen T, Goetz CG, Stebbins GT, Aarsland D, Alves G. A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol. 2010 Aug;67(8):996-1001. doi: 10.1001/archneurol.2010.166. PMID: 20697051.
  60. Lee AH, Weintraub D. Psychosis in Parkinson's disease without dementia: common and comorbid with other non-motor symptoms. Mov Disord. 2012 Jun;27(7):858-63. doi: 10.1002/mds.25003. Epub 2012 Jun 1. PMID: 22674352; PMCID: PMC3511789.
  61. Korczyn AD. Hallucinations in Parkinson's disease. Lancet. 2001 Sep 29;358(9287):1031-2. doi: 10.1016/S0140-6736(01)06230-4. PMID: 11589931.
  62. Williams-Gray CH, Foltynie T, Lewis SJ, Barker RA. Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options. CNS Drugs. 2006;20(6):477-505. doi: 10.2165/00023210-200620060-00004. PMID: 16734499.
  63. Lokk J, Delbari A. Clinical aspects of palliative care in advanced Parkinson's disease. BMC Palliat Care. 2012 Oct 25;11:20. doi: 10.1186/1472-684X-11-20. PMID: 23098090; PMCID: PMC3528486.
  64. Pham Nguyen TP, Abraham DS, Thibault D, Weintraub D, Willis AW. Low continuation of antipsychotic therapy in Parkinson disease - intolerance, ineffectiveness, or inertia? BMC Neurol. 2021 Jun 24;21(1):240. doi: 10.1186/s12883-021-02265-x. PMID: 34167473; PMCID: PMC8223332.
  65. Schrag A, Hovris A, Morley D, Quinn N, Jahanshahi M. Caregiver-burden in parkinson's disease is closely associated with psychiatric symptoms, falls, and disability. Parkinsonism Relat Disord. 2006 Jan;12(1):35-41. doi: 10.1016/j.parkreldis.2005.06.011. Epub 2005 Nov 3. PMID: 16271496.
  66. Juneja A, Anand K, Chandra M, Deshpande S, Dhamija R, Kathuria P, Mahajan R. Neuropsychiatric Symptoms and Caregiver Burden in Parkinson's Disease. Ann Indian Acad Neurol. 2020 Sep-Oct;23(5):656-660. doi: 10.4103/aian.AIAN_91_20. Epub 2020 Jul 8. PMID: 33623267; PMCID: PMC7887493.
  67. Chahine LM, Feldman R, Althouse A, Torsney B, Alzyoud L, Mantri S, Edison B, Albert S, Daeschler M, Kopil C, Marras C. Contribution of neuropsychiatric symptoms in Parkinson's disease to different domains of caregiver burden. J Neurol. 2021 Aug;268(8):2961-2972. doi: 10.1007/s00415-021-10443-7. Epub 2021 Feb 25. PMID: 33629181; PMCID: PMC8289810.
  68. Nene D, Yadav R. Neuropsychiatric Symptoms and Caregiver Burden in Parkinson's Disease: Mitigating the Lack of Awareness! Ann Indian Acad Neurol. 2020 Jul-Aug;23(4):575-576. doi: 10.4103/aian.AIAN_301_20. Epub 2020 Jul 8. PMID: 33223690; PMCID: PMC7657276.
  69. Tsai WC, Lin HC, Chang CC, Chang WN, Huang CC, Cheng KY, Wang HC, Lin WC, Hsiao SY, Lai YR, Lu CH, Tsai NW. Neuropsychiatric symptoms in Parkinson's disease: association with caregiver distress and disease severity. Int Psychogeriatr. 2020 Jun;32(6):733-739. doi: 10.1017/S1041610219001510. Epub 2019 Oct 24. PMID: 31647049.
  70. Terum TM, Andersen JR, Rongve A, Aarsland D, Svendsboe EJ, Testad I. The relationship of specific items on the Neuropsychiatric Inventory to caregiver burden in dementia: a systematic review. Int J Geriatr Psychiatry. 2017 Jul;32(7):703-717. doi: 10.1002/gps.4704. Epub 2017 Mar 20. PMID: 28317166.
  71. Steendam-Oldekamp E, Weerkamp N, Vonk JM, Bloem BR, van Laar T. Combined multidisciplinary in/outpatient rehabilitation delays definite nursing home admission in advanced Parkinson's disease patients. Front Neurol. 2023 Apr 13;14:1128891. doi: 10.3389/fneur.2023.1128891. PMID: 37122300; PMCID: PMC10133548.
  72. Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. J Am Geriatr Soc. 2000 Aug;48(8):938-42. doi: 10.1111/j.1532-5415.2000.tb06891.x. PMID: 10968298.
  73. Gonzalez MC, Dalen I, Maple-Grødem J, Tysnes OB, Alves G. Parkinson's disease clinical milestones and mortality. NPJ Parkinsons Dis. 2022 May 12;8(1):58. doi: 10.1038/s41531-022-00320-z. PMID: 35550520; PMCID: PMC9098431.
  74. Goetz CG, Stebbins GT. Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology. 1995 Apr;45(4):669-71. doi: 10.1212/wnl.45.4.669. PMID: 7723953.
  75. Goetz CG, Wuu J, Curgian LM, Leurgans S. Hallucinations and sleep disorders in PD: six-year prospective longitudinal study. Neurology. 2005 Jan 11;64(1):81-6. doi: 10.1212/01.WNL.0000148479.10865.FE. PMID: 15642908.
  76. Goetz CG, Wuu J, Curgian LM, Leurgans S. Hallucinations and sleep disorders in PD: six-year prospective longitudinal study. Neurology. 2005 Jan 11;64(1):81-6. doi: 10.1212/01.WNL.0000148479.10865.FE. PMID: 15642908.
  77. Zahodne LB, Fernandez HH. Parkinson's psychosis. Curr Treat Options Neurol. 2010 May;12(3):200-11. doi: 10.1007/s11940-010-0072-y. PMID: 20842582; PMCID: PMC3045857.
  78. Goetz CG, Ouyang B, Negron A, Stebbins GT. Hallucinations and sleep disorders in PD: ten-year prospective longitudinal study. Neurology. 2010 Nov 16;75(20):1773-9. doi: 10.1212/WNL.0b013e3181fd6158. Epub 2010 Oct 20. PMID: 20962287; PMCID: PMC2995381.
  79. Goetz CG, Leurgans S, Pappert EJ, Raman R, Stemer AB. Prospective longitudinal assessment of hallucinations in Parkinson's disease. Neurology. 2001 Dec 11;57(11):2078-82. doi: 10.1212/wnl.57.11.2078. PMID: 11739829.
  80. Taddei RN, Cankaya S, Dhaliwal S, Chaudhuri KR. Management of Psychosis in Parkinson's Disease: Emphasizing Clinical Subtypes and Pathophysiological Mechanisms of the Condition. Parkinsons Dis. 2017;2017:3256542. doi: 10.1155/2017/3256542. Epub 2017 Sep 12. PMID: 29104810; PMCID: PMC5613459.
  81. Zahodne LB, Fernandez HH. Pathophysiology and treatment of psychosis in Parkinson's disease: a review. Drugs Aging. 2008;25(8):665-82. doi: 10.2165/00002512-200825080-00004. PMID: 18665659; PMCID: PMC3045853.
  82. Zhang S, Ma Y. Emerging role of psychosis in Parkinson's disease: From clinical relevance to molecular mechanisms. World J Psychiatry. 2022 Sep 19;12(9):1127-1140. doi: 10.5498/wjp.v12.i9.1127. PMID: 36186499; PMCID: PMC9521528.
  83. Tost H, Alam T, Meyer-Lindenberg A. Dopamine and psychosis: theory, pathomechanisms and intermediate phenotypes. Neurosci Biobehav Rev. 2010 Apr;34(5):689-700. doi: 10.1016/j.neubiorev.2009.06.005. Epub 2009 Jun 24. PMID: 19559045; PMCID: PMC2838993.
  84. Powell A, Ireland C, Lewis SJG. Visual Hallucinations and the Role of Medications in Parkinson's Disease: Triggers, Pathophysiology, and Management. J Neuropsychiatry Clin Neurosci. 2020 Fall;32(4):334-343. doi: 10.1176/appi.neuropsych.19110316. Epub 2020 May 6. PMID: 32374649.
  85. Carmichael K, Sullivan B, Lopez E, Sun L, Cai H. Diverse midbrain dopaminergic neuron subtypes and implications for complex clinical symptoms of Parkinson's disease. Ageing Neurodegener Dis. 2021;1(4):10.20517/and.2021.07. doi: 10.20517/and.2021.07. Epub 2021 Jul 15. PMID: 34532720; PMCID: PMC8442626.
  86. Rizzi G, Tan KR. Dopamine and Acetylcholine, a Circuit Point of View in Parkinson's Disease. Front Neural Circuits. 2017 Dec 22;11:110. doi: 10.3389/fncir.2017.00110. PMID: 29311846; PMCID: PMC5744635.
  87. Caton M, Ochoa ELM, Barrantes FJ. The role of nicotinic cholinergic neurotransmission in delusional thinking. NPJ Schizophr. 2020 Jun 12;6(1):16. doi: 10.1038/s41537-020-0105-9. PMID: 32532978; PMCID: PMC7293341.
  88. Scarr E, Gibbons AS, Neo J, Udawela M, Dean B. Cholinergic connectivity: it's implications for psychiatric disorders. Front Cell Neurosci. 2013 May 3;7:55. doi: 10.3389/fncel.2013.00055. PMID: 23653591; PMCID: PMC3642390.
  89. Stang CD, Mullan AF, Camerucci E, Hajeb M, Turcano P, Martin P, Mielke MM, Josephs KA, Splett M, Abler V, Boeve BF, Bower JH, Savica R. Incidence, Prevalence, and Mortality of Psychosis Associated with Parkinson's Disease (1991-2010). J Parkinsons Dis. 2022;12(4):1319-1327. doi: 10.3233/JPD-213035. PMID: 35213389; PMCID: PMC9336204.
  90. Mohammad ME, Vizcarra JA, Garcia X, Patel S, Margolius A, Yu XX, Fernandez HH. Impact of behavioral side effects on the management of Parkinson patients treated with dopamine agonists. Clin Park Relat Disord. 2021 Mar 2;4:100091. doi: 10.1016/j.prdoa.2021.100091. PMID: 34316669; PMCID: PMC8299972.
  91. Cummings JL. Behavioral complications of drug treatment of Parkinson's disease. J Am Geriatr Soc. 1991 Jul;39(7):708-16. doi: 10.1111/j.1532-5415.1991.tb03627.x. PMID: 2061539.
  92. Graham JM, Grünewald RA, Sagar HJ. Hallucinosis in idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 1997 Oct;63(4):434-40. doi: 10.1136/jnnp.63.4.434. PMID: 9343119; PMCID: PMC2169767.
  93. Inzelberg R, Kipervasser S, Korczyn AD. Auditory hallucinations in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1998 Apr;64(4):533-5. doi: 10.1136/jnnp.64.4.533. PMID: 9576549; PMCID: PMC2170055.
  94. Aarsland D, Larsen JP, Cummins JL, Laake K. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol. 1999 May;56(5):595-601. doi: 10.1001/archneur.56.5.595. PMID: 10328255.
  95. Fénelon G, Mahieux F, Huon R, Ziégler M. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain. 2000 Apr;123 ( Pt 4):733-45. doi: 10.1093/brain/123.4.733. PMID: 10734005.
  96. Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2001 Jun;70(6):734-8. doi: 10.1136/jnnp.70.6.734. PMID: 11385005; PMCID: PMC1737419.
  97. Schrag A, Ben-Shlomo Y, Quinn N. How common are complications of Parkinson's disease? J Neurol. 2002 Apr;249(4):419-23. doi: 10.1007/s004150200032. PMID: 11967646.
  98. Marsh L, Williams JR, Rocco M, Grill S, Munro C, Dawson TM. Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology. 2004 Jul 27;63(2):293-300. doi: 10.1212/01.wnl.0000129843.15756.a3. PMID: 15277623.
  99. Merims D, Shabtai H, Korczyn AD, Peretz C, Weizman N, Giladi N. Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson's disease. J Neural Transm (Vienna). 2004 Oct;111(10-11):1447-53. doi: 10.1007/s00702-004-0209-9. PMID: 15480845.
  100. Paleacu D, Schechtman E, Inzelberg R. Association between family history of dementia and hallucinations in Parkinson disease. Neurology. 2005 May 24;64(10):1712-5. doi: 10.1212/01.WNL.0000161872.85903.8E. PMID: 15911796.
  101. Meral H, Aydemir T, Ozer F, Ozturk O, Ozben S, Erol C, Cetin S, Hanoglu L, Ozkayran T, Yilsen M. Relationship between visual hallucinations and REM sleep behavior disorder in patients with Parkinson's disease. Clin Neurol Neurosurg. 2007 Dec;109(10):862-7. doi: 10.1016/j.clineuro.2007.08.010. PMID: 17913346.
  102. Williams DR, Warren JD, Lees AJ. Using the presence of visual hallucinations to differentiate Parkinson's disease from atypical parkinsonism. J Neurol Neurosurg Psychiatry. 2008 Jun;79(6):652-5. doi: 10.1136/jnnp.2007.124677. Epub 2007 Sep 14. PMID: 17872984.
  103. Papapetropoulos S, Katzen H, Schrag A, Singer C, Scanlon BK, Nation D, Guevara A, Levin B. A questionnaire-based (UM-PDHQ) study of hallucinations in Parkinson's disease. BMC Neurol. 2008 Jun 20;8:21. doi: 10.1186/1471-2377-8-21. PMID: 18570642; PMCID: PMC2443167.
  104. Fénelon G, Soulas T, Zenasni F, Cleret de Langavant L. The changing face of Parkinson's disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria. Mov Disord. 2010 Apr 30;25(6):763-6. doi: 10.1002/mds.22839. PMID: 20437542; PMCID: PMC2891710.
  105. Mack J, Rabins P, Anderson K, Goldstein S, Grill S, Hirsch ES, Lehmann S, Little JT, Margolis RL, Palanci J, Pontone G, Weiss H, Williams JR, Marsh L. Prevalence of psychotic symptoms in a community-based Parkinson disease sample. Am J Geriatr Psychiatry. 2012 Feb;20(2):123-32. doi: 10.1097/JGP.0b013e31821f1b41. PMID: 21617521; PMCID: PMC3168582.
  106. Chou KL, Messing S, Oakes D, Feldman PD, Breier A, Friedman JH. Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments. Clin Neuropharmacol. 2005 Sep-Oct;28(5):215-9. doi: 10.1097/01.wnf.0000180228.77802.32. PMID: 16239760.
  107. Schrag A, Dodel R, Spottke A, Bornschein B, Siebert U, Quinn NP. Rate of clinical progression in Parkinson's disease. A prospective study. Mov Disord. 2007 May 15;22(7):938-45. doi: 10.1002/mds.21429. PMID: 17415791.
  108. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord. 2008 Apr 30;23(6):837-44. doi: 10.1002/mds.21956. PMID: 18307261.
  109. Biglan KM, Holloway RG Jr, McDermott MP, Richard IH; Parkinson Study Group CALM-PD Investigators. Risk factors for somnolence, edema, and hallucinations in early Parkinson disease. Neurology. 2007 Jul 10;69(2):187-95. doi: 10.1212/01.wnl.0000265593.34438.00. PMID: 17620552.
  110. Mok VWL, Chan LG, Goh JCB, Tan LCS. Psychosis in Parkinson's disease in a Southeast Asian cohort: prevalence and clinical correlates. Singapore Med J. 2022 Dec;63(12):702-708. doi: 10.11622/smedj.2021182. Epub 2021 Dec 15. PMID: 34911181; PMCID: PMC9875879.
  111. Williams DR, Lees AJ. Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study. Lancet Neurol. 2005 Oct;4(10):605-10. doi: 10.1016/S1474-4422(05)70146-0. PMID: 16168928.
  112. Fénelon G, Alves G. Epidemiology of psychosis in Parkinson's disease. J Neurol Sci. 2010 Feb 15;289(1-2):12-7. doi: 10.1016/j.jns.2009.08.014. Epub 2009 Sep 8. PMID: 19740486.
  113. Ffytche DH, Pereira JB, Ballard C, Chaudhuri KR, Weintraub D, Aarsland D. Risk factors for early psychosis in PD: insights from the Parkinson's Progression Markers Initiative. J Neurol Neurosurg Psychiatry. 2017 Apr;88(4):325-331. doi: 10.1136/jnnp-2016-314832. PMID: 28315846; PMCID: PMC5362125.
  114. Chaudhuri KR, Healy DG, Schapira AH; National Institute for Clinical Excellence. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 2006 Mar;5(3):235-45. doi: 10.1016/S1474-4422(06)70373-8. PMID: 16488379.
  115. Factor SA, Feustel PJ, Friedman JH, Comella CL, Goetz CG, Kurlan R, Parsa M, Pfeiffer R; Parkinson Study Group. Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology. 2003 Jun 10;60(11):1756-61. doi: 10.1212/01.wnl.0000068010.82167.cf. PMID: 12796526.
  116. Pappert EJ, Goetz CG, Niederman FG, Raman R, Leurgans S. Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease. Mov Disord. 1999 Jan;14(1):117-21. doi: 10.1002/1531-8257(199901)14:1<117::aid-mds1019>3.0.co;2-0. PMID: 9918353.
  117. Simonet C, Tolosa E, Camara A, Valldeoriola F. Emergencies and critical issues in Parkinson's disease. Pract Neurol. 2020 Feb;20(1):15-25. doi: 10.1136/practneurol-2018-002075. Epub 2019 Aug 19. PMID: 31427383; PMCID: PMC7029239.
  118. Gama RL, de Bruin VM, de Bruin PF, Távora DG, Lopes EM, Jorge IF, Bittencourt LR, Tufik S. Risk factors for visual hallucinations in patients with Parkinson's disease. Neurol Res. 2015 Feb;37(2):112-6. doi: 10.1179/1743132814Y.0000000418. Epub 2014 Jul 8. PMID: 25002179.
  119. Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014 Apr 23-30;311(16):1670-83. doi: 10.1001/jama.2014.3654. PMID: 24756517.
  120. Fernandez HH, Aarsland D, Fénelon G, Friedman JH, Marsh L, Tröster AI, Poewe W, Rascol O, Sampaio C, Stebbins GT, Goetz CG. Scales to assess psychosis in Parkinson's disease: Critique and recommendations. Mov Disord. 2008 Mar 15;23(4):484-500. doi: 10.1002/mds.21875. PMID: 18175343.
  121. Martinez-Ramirez D, Okun MS, Jaffee MS. Parkinson's disease psychosis: therapy tips and the importance of communication between neurologists and psychiatrists. Neurodegener Dis Manag. 2016 Aug;6(4):319-30. doi: 10.2217/nmt-2016-0009. Epub 2016 Jul 13. PMID: 27408981; PMCID: PMC5066136.
  122. Thanvi BR, Lo TC, Harsh DP. Psychosis in Parkinson's disease. Postgrad Med J. 2005 Oct;81(960):644-6. doi: 10.1136/pgmj.2004.032029. PMID: 16210460; PMCID: PMC1743370.
  123. Goetz CG, Wuu J, Curgian L, Leurgans S. Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson's disease patients. Mov Disord. 2006 Feb;21(2):267-70. doi: 10.1002/mds.20701. PMID: 16161144.
  124. Amar BR, Yadav R, Janardhan Reddy YC, Pal PK. A clinical profile of patients with Parkinson's disease and psychosis. Ann Indian Acad Neurol. 2014 Apr;17(2):187-92. doi: 10.4103/0972-2327.132625. PMID: 25024570; PMCID: PMC4090845.
  125. Chang A, Fox SH. Psychosis in Parkinson's Disease: Epidemiology, Pathophysiology, and Management. Drugs. 2016 Jul;76(11):1093-118. doi: 10.1007/s40265-016-0600-5. Erratum in: Drugs. 2016 Sep;76(13):1319. Dosage error in article text. PMID: 27312429.
  126. Ffytche DH, Creese B, Politis M, Chaudhuri KR, Weintraub D, Ballard C, Aarsland D. The psychosis spectrum in Parkinson disease. Nat Rev Neurol. 2017 Feb;13(2):81-95. doi: 10.1038/nrneurol.2016.200. Epub 2017 Jan 20. PMID: 28106066; PMCID: PMC5656278.
  127. Zhong J, Wu S, Zhao Y, Chen H, Zhao N, Zheng K, Zhao Z, Chen W, Wang B, Wu K. Why psychosis is frequently associated with Parkinson's disease? Neural Regen Res. 2013 Sep 25;8(27):2548-56. doi: 10.3969/j.issn.1673-5374.2013.27.006. PMID: 25206565; PMCID: PMC4145938.
  128. Barnes J, David AS. Visual hallucinations in Parkinson's disease: a review and phenomenological survey. J Neurol Neurosurg Psychiatry. 2001 Jun;70(6):727-33. doi: 10.1136/jnnp.70.6.727. PMID: 11385004; PMCID: PMC1737396.
  129. Vignando M, Ffytche D, Lewis SJG, Lee PH, Chung SJ, Weil RS, Hu MT, Mackay CE, Griffanti L, Pins D, Dujardin K, Jardri R, Taylor JP, Firbank M, McAlonan G, Mak HKF, Ho SL, Mehta MA. Author Correction: Mapping brain structural differences and neuroreceptor correlates in Parkinson's disease visual hallucinations. Nat Commun. 2022 Feb 15;13(1):971. doi: 10.1038/s41467-022-28491-6. Erratum for: Nat Commun. 2022 Jan 26;13(1):519. PMID: 35169136; PMCID: PMC8847348.
  130. Mantovani E, Zucchella C, Argyriou AA, Tamburin S. Treatment for cognitive and neuropsychiatric non-motor symptoms in Parkinson's disease: current evidence and future perspectives. Expert Rev Neurother. 2023 Jan;23(1):25-43. doi: 10.1080/14737175.2023.2173576. Epub 2023 Feb 9. PMID: 36701529.
  131. Chendo I, Fabbri M, Godinho C, Moiron Simões R, Severiano Sousa C, Coelho M, Voon V, Ferreira JJ. High frequency of psychosis in late-stage Parkinsońs disease. Clin Park Relat Disord. 2021 Nov 24;5:100119. doi: 10.1016/j.prdoa.2021.100119. PMID: 34988427; PMCID: PMC8710406.
  132. Pagonabarraga J, Martinez-Horta S, Fernández de Bobadilla R, Pérez J, Ribosa-Nogué R, Marín J, Pascual-Sedano B, García C, Gironell A, Kulisevsky J. Minor hallucinations occur in drug-naive Parkinson's disease patients, even from the premotor phase. Mov Disord. 2016 Jan;31(1):45-52. doi: 10.1002/mds.26432. Epub 2015 Sep 26. Erratum in: Mov Disord. 2016 Mar;31(3):433. PMID: 26408291.
  133. Rana AQ, Siddiqui I, Zangeneh M, Fattah A, Awan N, Yousuf MS. Predicting treatment-seeking for visual hallucinations among Parkinson's disease patients. Psychiatry Clin Neurosci. 2013 Nov;67(7):509-16. doi: 10.1111/pcn.12083. Epub 2013 Sep 2. PMID: 23992392.
  134. Llorca PM, Pereira B, Jardri R, Chereau-Boudet I, Brousse G, Misdrahi D, Fénelon G, Tronche AM, Schwan R, Lançon C, Marques A, Ulla M, Derost P, Debilly B, Durif F, de Chazeron I. Hallucinations in schizophrenia and Parkinson's disease: an analysis of sensory modalities involved and the repercussion on patients. Sci Rep. 2016 Dec 1;6:38152. doi: 10.1038/srep38152. PMID: 27905557; PMCID: PMC5131286.
  135. Kulisevsky J, Pagonabarraga J, Pascual-Sedano B, García-Sánchez C, Gironell A; Trapecio Group Study. Prevalence and correlates of neuropsychiatric symptoms in Parkinson's disease without dementia. Mov Disord. 2008 Oct 15;23(13):1889-96. doi: 10.1002/mds.22246. PMID: 18709682.
  136. Pacchetti C, Manni R, Zangaglia R, Mancini F, Marchioni E, Tassorelli C, Terzaghi M, Ossola M, Martignoni E, Moglia A, Nappi G. Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson's disease. Mov Disord. 2005 Nov;20(11):1439-48. doi: 10.1002/mds.20582. PMID: 16028215.
  137. Riedel O, Klotsche J, Spottke A, Deuschl G, Förstl H, Henn F, Heuser I, Oertel W, Reichmann H, Riederer P, Trenkwalder C, Dodel R, Wittchen HU. Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson's disease. J Neurol. 2010 Jul;257(7):1073-82. doi: 10.1007/s00415-010-5465-z. Epub 2010 Feb 6. PMID: 20140443.
  138. Solla P, Cannas A, Ibba FC, Loi F, Corona M, Orofino G, Marrosu MG, Marrosu F. Gender differences in motor and non-motor symptoms among Sardinian patients with Parkinson's disease. J Neurol Sci. 2012 Dec 15;323(1-2):33-9. doi: 10.1016/j.jns.2012.07.026. Epub 2012 Aug 27. PMID: 22935408.
  139. Verbaan D, van Rooden SM, Visser M, Marinus J, Emre M, van Hilten JJ. Psychotic and compulsive symptoms in Parkinson's disease. Mov Disord. 2009 Apr 15;24(5):738-44. doi: 10.1002/mds.22453. PMID: 19133665.
  140. Naimark D, Jackson E, Rockwell E, Jeste DV. Psychotic symptoms in Parkinson's disease patients with dementia. J Am Geriatr Soc. 1996 Mar;44(3):296-9. doi: 10.1111/j.1532-5415.1996.tb00918.x. PMID: 8600200.
  141. Martinez-Martin P, Rodriguez-Blazquez C, Forjaz MJ, Frades-Payo B, Agüera-Ortiz L, Weintraub D, Riesco A, Kurtis MM, Chaudhuri KR. Neuropsychiatric symptoms and caregiver's burden in Parkinson's disease. Parkinsonism Relat Disord. 2015 Jun;21(6):629-34. doi: 10.1016/j.parkreldis.2015.03.024. Epub 2015 Apr 9. PMID: 25892660.
  142. Aarsland D, Brønnick K, Ehrt U, De Deyn PP, Tekin S, Emre M, Cummings JL. Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry. 2007 Jan;78(1):36-42. doi: 10.1136/jnnp.2005.083113. Epub 2006 Jul 4. PMID: 16820421; PMCID: PMC2117797.
  143. Poletti M, Perugi G, Logi C, Romano A, Del Dotto P, Ceravolo R, Rossi G, Pepe P, Dell'Osso L, Bonuccelli U. Dopamine agonists and delusional jealousy in Parkinson's disease: a cross-sectional prevalence study. Mov Disord. 2012 Nov;27(13):1679-82. doi: 10.1002/mds.25129. Epub 2012 Nov 13. PMID: 23150469.
  144. Roane DM, Rogers JD, Robinson JH, Feinberg TE. Delusional misidentification in association with parkinsonism. J Neuropsychiatry Clin Neurosci. 1998 Spring;10(2):194-8. doi: 10.1176/jnp.10.2.194. PMID: 9608408.
  145. Stewart JT. Frégoli syndrome associated with levodopa treatment. Mov Disord. 2008 Jan 30;23(2):308-9. doi: 10.1002/mds.21843. PMID: 18044770.
  146. Pagonabarraga J, Llebaria G, García-Sánchez C, Pascual-Sedano B, Gironell A, Kulisevsky J. A prospective study of delusional misidentification syndromes in Parkinson's disease with dementia. Mov Disord. 2008 Feb 15;23(3):443-8. doi: 10.1002/mds.21864. PMID: 18076112.
  147. Goetz CG, Fan W, Leurgans S, Bernard B, Stebbins GT. The malignant course of "benign hallucinations" in Parkinson disease. Arch Neurol. 2006 May;63(5):713-6. doi: 10.1001/archneur.63.5.713. PMID: 16682540.
  148. Goetz CG, Fan W, Leurgans S. Antipsychotic medication treatment for mild hallucinations in Parkinson's disease: Positive impact on long-term worsening. Mov Disord. 2008 Aug 15;23(11):1541-5. doi: 10.1002/mds.22132. PMID: 18567004.
  149. Zhong M, Gu R, Zhu S, Bai Y, Wu Z, Jiang X, Shen B, Zhu J, Pan Y, Yan J, Zhang L. Prevalence and Risk Factors for Minor Hallucinations in Patients with Parkinson's Disease. Behav Neurol. 2021 Oct 4;2021:3469706. doi: 10.1155/2021/3469706. PMID: 34646400; PMCID: PMC8505047.
  150. Factor SA, Scullin MK, Sollinger AB, Land JO, Wood-Siverio C, Zanders L, Freeman A, Bliwise DL, McDonald WM, Goldstein FC. Cognitive correlates of hallucinations and delusions in Parkinson's disease. J Neurol Sci. 2014 Dec 15;347(1-2):316-21. doi: 10.1016/j.jns.2014.10.033. Epub 2014 Oct 23. PMID: 25466695.
  151. Factor SA, McDonald WM, Goldstein FC. The role of neurotransmitters in the development of Parkinson's disease-related psychosis. Eur J Neurol. 2017 Oct;24(10):1244-1254. doi: 10.1111/ene.13376. Epub 2017 Jul 31. PMID: 28758318.
  152. Byrne P. Managing the acute psychotic episode. BMJ. 2007 Mar 31;334(7595):686-92. doi: 10.1136/bmj.39148.668160.80. PMID: 17395949; PMCID: PMC1839209.
  153. Brendel RW, Stern TA. Psychotic symptoms in the elderly. Prim Care Companion J Clin Psychiatry. 2005;7(5):238-41. doi: 10.4088/pcc.v07n0506. PMID: 16308581; PMCID: PMC1257410.
  154. Arciniegas DB. Psychosis. Continuum (Minneap Minn). 2015 Jun;21(3 Behavioral Neurology and Neuropsychiatry):715-36. doi: 10.1212/01.CON.0000466662.89908.e7. PMID: 26039850; PMCID: PMC4455840.
  155. Sawada H, Oeda T, Yamamoto K, Umemura A, Tomita S, Hayashi R, Kohsaka M, Kawamura T. Trigger medications and patient-related risk factors for Parkinson disease psychosis requiring anti-psychotic drugs: a retrospective cohort study. BMC Neurol. 2013 Oct 12;13:145. doi: 10.1186/1471-2377-13-145. PMID: 24119306; PMCID: PMC3879653.
  156. Poewe W. Psychosis in Parkinson's disease. Mov Disord. 2003 Sep;18 Suppl 6:S80-7. doi: 10.1002/mds.10567. PMID: 14502660.
  157. Fénelon G. Psychosis in Parkinson's disease: phenomenology, frequency, risk factors, and current understanding of pathophysiologic mechanisms. CNS Spectr. 2008 Mar;13(3 Suppl 4):18-25. doi: 10.1017/s1092852900017284. PMID: 18323763.
  158. Huse DM, Schulman K, Orsini L, Castelli-Haley J, Kennedy S, Lenhart G. Burden of illness in Parkinson's disease. Mov Disord. 2005 Nov;20(11):1449-54. doi: 10.1002/mds.20609. PMID: 16007641.
  159. Keränen T, Kaakkola S, Sotaniemi K, Laulumaa V, Haapaniemi T, Jolma T, Kola H, Ylikoski A, Satomaa O, Kovanen J, Taimela E, Haapaniemi H, Turunen H, Takala A. Economic burden and quality of life impairment increase with severity of PD. Parkinsonism Relat Disord. 2003 Jan;9(3):163-8. doi: 10.1016/s1353-8020(02)00097-4. PMID: 12573872.
  160. Johnson SJ, Kaltenboeck A, Diener M, Birnbaum HG, Grubb E, Castelli-Haley J, Siderowf AD. Costs of Parkinson's disease in a privately insured population. Pharmacoeconomics. 2013 Sep;31(9):799-806. doi: 10.1007/s40273-013-0075-0. PMID: 23907717; PMCID: PMC3757266.
  161. Kaltenboeck A, Johnson SJ, Davis MR, Birnbaum HG, Carroll CA, Tarrants ML, Siderowf AD. Direct costs and survival of medicare beneficiaries with early and advanced Parkinson's disease. Parkinsonism Relat Disord. 2012 May;18(4):321-6. doi: 10.1016/j.parkreldis.2011.11.015. Epub 2011 Dec 16. PMID: 22177623.
  162. Hermanowicz N, Edwards K. Parkinson's disease psychosis: symptoms, management, and economic burden. Am J Manag Care. 2015 Aug;21(10 Suppl):s199-206. PMID: 26296199.
  163. Yang JX, Chen L. Economic Burden Analysis of Parkinson's Disease Patients in China. Parkinsons Dis. 2017;2017:8762939. doi: 10.1155/2017/8762939. Epub 2017 Jun 14. PMID: 28695039; PMCID: PMC5488490.
  164. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology. 1993 Nov;43(11):2227-9. doi: 10.1212/wnl.43.11.2227. PMID: 8232934.
  165. Wolters EC. Dopaminomimetic psychosis in Parkinson's disease patients: diagnosis and treatment. Neurology. 1999;52(7 Suppl 3):S10-3. PMID: 10227604.
  166. Stahl SM. Parkinson's disease psychosis as a serotonin-dopamine imbalance syndrome. CNS Spectr. 2016 Oct;21(5):355-359. doi: 10.1017/S1092852916000602. PMID: 27686027.
  167. Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain. 2002 Feb;125(Pt 2):391-403. doi: 10.1093/brain/awf033. PMID: 11844739.
  168. Birkmayer W, Riederer P. Responsibility of extrastriatal areas for the appearance of psychotic symptoms (clinical and biochemical human post-mortem findings). J Neural Transm. 1975;37(2):175-82. doi: 10.1007/BF01663632. PMID: 1185162.
  169. Glennon RA, Titeler M, McKenney JD. Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci. 1984 Dec 17;35(25):2505-11. doi: 10.1016/0024-3205(84)90436-3. PMID: 6513725.
  170. Titeler M, Lyon RA, Glennon RA. Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens. Psychopharmacology (Berl). 1988;94(2):213-6. doi: 10.1007/BF00176847. PMID: 3127847.
  171. Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry. 2001 Mar;158(3):360-9. doi: 10.1176/appi.ajp.158.3.360. PMID: 11229973.
  172. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. PMID: 11873706.
  173. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther. 1989 Oct;251(1):238-46. PMID: 2571717.
  174. Ballanger B, Strafella AP, van Eimeren T, Zurowski M, Rusjan PM, Houle S, Fox SH. Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch Neurol. 2010 Apr;67(4):416-21. doi: 10.1001/archneurol.2010.35. PMID: 20385906.
  175. Huot P, Johnston TH, Darr T, Hazrati LN, Visanji NP, Pires D, Brotchie JM, Fox SH. Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations. Mov Disord. 2010 Jul 30;25(10):1399-408. doi: 10.1002/mds.23083. PMID: 20629135.
  176. Grosch J, Winkler J, Kohl Z. Early Degeneration of Both Dopaminergic and Serotonergic Axons - A Common Mechanism in Parkinson's Disease. Front Cell Neurosci. 2016 Dec 22;10:293. doi: 10.3389/fncel.2016.00293. PMID: 28066188; PMCID: PMC5177648.
  177. Politis M, Loane C. Serotonergic dysfunction in Parkinson's disease and its relevance to disability. ScientificWorldJournal. 2011;11:1726-34. doi: 10.1100/2011/172893. Epub 2011 Oct 17. PMID: 22125431; PMCID: PMC3201695.
  178. Qamhawi Z, Towey D, Shah B, Pagano G, Seibyl J, Marek K, Borghammer P, Brooks DJ, Pavese N. Clinical correlates of raphe serotonergic dysfunction in early Parkinson's disease. Brain. 2015 Oct;138(Pt 10):2964-73. doi: 10.1093/brain/awv215. Epub 2015 Jul 23. PMID: 26209314.
  179. Zhu K, van Hilten JJ, Putter H, Marinus J. Risk factors for hallucinations in Parkinson's disease: results from a large prospective cohort study. Mov Disord. 2013 Jun;28(6):755-62. doi: 10.1002/mds.25389. Epub 2013 Mar 20. PMID: 23520046.
  180. Giladi N, Treves TA, Paleacu D, Shabtai H, Orlov Y, Kandinov B, Simon ES, Korczyn AD. Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease. J Neural Transm (Vienna). 2000;107(1):59-71. doi: 10.1007/s007020050005. PMID: 10809404.
  181. Gallagher DA, Schrag A. Psychosis, apathy, depression and anxiety in Parkinson's disease. Neurobiol Dis. 2012 Jun;46(3):581-9. doi: 10.1016/j.nbd.2011.12.041. Epub 2012 Jan 3. PMID: 22245219.
  182. Han JW, Ahn YD, Kim WS, Shin CM, Jeong SJ, Song YS, Bae YJ, Kim JM. Psychiatric Manifestation in Patients with Parkinson's Disease. J Korean Med Sci. 2018 Nov 1;33(47):e300. doi: 10.3346/jkms.2018.33.e300. PMID: 30450025; PMCID: PMC6236081.
  183. Dujardin K, Sgambato V. Neuropsychiatric Disorders in Parkinson's Disease: What Do We Know About the Role of Dopaminergic and Non-dopaminergic Systems? Front Neurosci. 2020 Jan 29;14:25. doi: 10.3389/fnins.2020.00025. PMID: 32063833; PMCID: PMC7000525.
  184. Thanvi BR, Munshi SK, Vijaykumar N, Lo TC. Neuropsychiatric non-motor aspects of Parkinson's disease. Postgrad Med J. 2003 Oct;79(936):561-5. doi: 10.1136/pmj.79.936.561. PMID: 14612597; PMCID: PMC1742855.
  185. Russo M, Carrarini C, Dono F, Rispoli MG, Di Pietro M, Di Stefano V, Ferri L, Bonanni L, Sensi SL, Onofrj M. The Pharmacology of Visual Hallucinations in Synucleinopathies. Front Pharmacol. 2019 Dec 9;10:1379. doi: 10.3389/fphar.2019.01379. PMID: 31920635; PMCID: PMC6913661.
  186. Kurita A, Koshikawa H, Akiba T, Seki K, Ishikawa H, Suzuki M. Visual Hallucinations and Impaired Conscious Visual Perception in Parkinson Disease. J Geriatr Psychiatry Neurol. 2020 Nov;33(6):377-385. doi: 10.1177/0891988719892318. Epub 2019 Dec 6. PMID: 31808354.
  187. Juárez Olguín H, Calderón Guzmán D, Hernández García E, Barragán Mejía G. The Role of Dopamine and Its Dysfunction as a Consequence of Oxidative Stress. Oxid Med Cell Longev. 2016;2016:9730467. doi: 10.1155/2016/9730467. Epub 2015 Dec 6. PMID: 26770661; PMCID: PMC4684895.
  188. Sulzer D, Cragg SJ, Rice ME. Striatal dopamine neurotransmission: regulation of release and uptake. Basal Ganglia. 2016 Aug;6(3):123-148. doi: 10.1016/j.baga.2016.02.001. PMID: 27141430; PMCID: PMC4850498.
  189. Ranjbar-Slamloo Y, Fazlali Z. Dopamine and Noradrenaline in the Brain; Overlapping or Dissociate Functions? Front Mol Neurosci. 2020 Jan 21;12:334. doi: 10.3389/fnmol.2019.00334. PMID: 32038164; PMCID: PMC6986277.
  190. Jackson ME, Moghaddam B. Amygdala regulation of nucleus accumbens dopamine output is governed by the prefrontal cortex. J Neurosci. 2001 Jan 15;21(2):676-81. doi: 10.1523/JNEUROSCI.21-02-00676.2001. PMID: 11160446; PMCID: PMC6763812.
  191. Goldman JG. New thoughts on thought disorders in Parkinson's disease: review of current research strategies and challenges. Parkinsons Dis. 2011 Mar 2;2011:675630. doi: 10.4061/2011/675630. PMID: 21403865; PMCID: PMC3049364.
  192. Brisch R, Saniotis A, Wolf R, Bielau H, Bernstein HG, Steiner J, Bogerts B, Braun K, Jankowski Z, Kumaratilake J, Henneberg M, Gos T. The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue. Front Psychiatry. 2014 May 19;5:47. doi: 10.3389/fpsyt.2014.00047. Erratum in: Front Psychiatry. 2014;5:110. Braun, Anna Katharina [corrected to Braun, Katharina]; Kumaritlake, Jaliya [corrected to Kumaratilake, Jaliya]. PMID: 24904434; PMCID: PMC4032934.
  193. Li P, Snyder GL, Vanover KE. Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future. Curr Top Med Chem. 2016;16(29):3385-3403. doi: 10.2174/1568026616666160608084834. PMID: 27291902; PMCID: PMC5112764.
  194. Ecker D, Unrath A, Kassubek J, Sabolek M. Dopamine Agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study. BMC Neurol. 2009 Jun 10;9:23. doi: 10.1186/1471-2377-9-23. PMID: 19515253; PMCID: PMC2704166.
  195. Carta M, Carlsson T, Kirik D, Björklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain. 2007 Jul;130(Pt 7):1819-33. doi: 10.1093/brain/awm082. Epub 2007 Apr 23. PMID: 17452372.
  196. Laprade N, Radja F, Reader TA, Soghomonian JJ. Dopamine receptor agonists regulate levels of the serotonin 5-HT2A receptor and its mRNA in a subpopulation of rat striatal neurons. J Neurosci. 1996 Jun 1;16(11):3727-36. doi: 10.1523/JNEUROSCI.16-11-03727.1996. PMID: 8642415; PMCID: PMC6578831.
  197. Radja F, Descarries L, Dewar KM, Reader TA. Serotonin 5-HT1 and 5-HT2 receptors in adult rat brain after neonatal destruction of nigrostriatal dopamine neurons: a quantitative autoradiographic study. Brain Res. 1993 Mar 26;606(2):273-85. doi: 10.1016/0006-8993(93)90995-y. PMID: 8490720.
  198. Nausieda PA, Tanner CM, Klawans HL. Serotonergically active agents in levodopa-induced psychiatric toxicity reactions. Adv Neurol. 1983;37:23-32. PMID: 6858774.
  199. Weintraub D, Hurtig HI. Presentation and management of psychosis in Parkinson's disease and dementia with Lewy bodies. Am J Psychiatry. 2007 Oct;164(10):1491-8. doi: 10.1176/appi.ajp.2007.07040715. PMID: 17898337; PMCID: PMC2137166.
  200. Camicioli R, Fisher N. Progress in clinical neurosciences: Parkinson's disease with dementia and dementia with Lewy bodies. Can J Neurol Sci. 2004 Feb;31(1):7-21. doi: 10.1017/s0317167100002791. PMID: 15038467.
  201. Perry E, Walker M, Grace J, Perry R. Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci. 1999 Jun;22(6):273-80. doi: 10.1016/s0166-2236(98)01361-7. PMID: 10354606.
  202. Chen JJ. Treatment of psychotic symptoms in patients with Parkinson disease. Ment Health Clin. 2018 Mar 23;7(6):262-270. doi: 10.9740/mhc.2017.11.262. PMID: 29955532; PMCID: PMC6007727.
  203. Burn D, Emre M, McKeith I, De Deyn PP, Aarsland D, Hsu C, Lane R. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord. 2006 Nov;21(11):1899-907. doi: 10.1002/mds.21077. PMID: 16960863.
  204. Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev. 2012 Mar 14;2012(3):CD006504. doi: 10.1002/14651858.CD006504.pub2. PMID: 22419314; PMCID: PMC8985413.
  205. Perry EK, Perry RH. Acetylcholine and hallucinations: disease-related compared to drug-induced alterations in human consciousness. Brain Cogn. 1995 Aug;28(3):240-58. doi: 10.1006/brcg.1995.1255. PMID: 8546852.
  206. Bosboom JL, Stoffers D, Wolters ECh. The role of acetylcholine and dopamine in dementia and psychosis in Parkinson's disease. J Neural Transm Suppl. 2003;(65):185-95. doi: 10.1007/978-3-7091-0643-3_11. PMID: 12946056.
  207. Perry EK, Irving D, Kerwin JM, McKeith IG, Thompson P, Collerton D, Fairbairn AF, Ince PG, Morris CM, Cheng AV, et al. Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson's and distinction from Alzheimer disease. Alzheimer Dis Assoc Disord. 1993 Summer;7(2):69-79. doi: 10.1097/00002093-199307020-00002. PMID: 8347330.
  208. Fioravanti V, Benuzzi F, Codeluppi L, Contardi S, Cavallieri F, Nichelli P, Valzania F. MRI correlates of Parkinson's disease progression: a voxel based morphometry study. Parkinsons Dis. 2015;2015:378032. doi: 10.1155/2015/378032. Epub 2015 Jan 6. PMID: 25628916; PMCID: PMC4299788.
  209. Riederer P, Lange KW, Kornhuber J, Danielczyk W. Glutamatergic-dopaminergic balance in the brain. Its importance in motor disorders and schizophrenia. Arzneimittelforschung. 1992 Feb;42(2A):265-8. PMID: 1350197.
  210. Zhang Z, Zhang S, Fu P, Zhang Z, Lin K, Ko JK, Yung KK. Roles of Glutamate Receptors in Parkinson's Disease. Int J Mol Sci. 2019 Sep 6;20(18):4391. doi: 10.3390/ijms20184391. PMID: 31500132; PMCID: PMC6769661.
  211. Pagonabarraga J, Tinazzi M, Caccia C, Jost WH. The role of glutamatergic neurotransmission in the motor and non-motor symptoms in Parkinson's disease: Clinical cases and a review of the literature. J Clin Neurosci. 2021 Aug;90:178-183. doi: 10.1016/j.jocn.2021.05.056. Epub 2021 Jun 10. PMID: 34275546.
  212. Rodríguez-Violante M, Cervantes-Arriaga A, González-Latapí P, León-Ortiz P, de la Fuente-Sandoval C, Corona T. Proton Magnetic Resonance Spectroscopy Changes in Parkinson's Disease With and Without Psychosis. Rev Invest Clin. 2015 Jul-Aug;67(4):227-34. PMID: 26426588.
  213. Lenka A, Ingalhalikar M, Shah A, Saini J, Arumugham SS, Hegde S, George L, Reddy V, Reddy YCJ, Yadav R, Pal PK. Hippocampal subfield atrophy in patients with Parkinson's disease and psychosis. J Neural Transm (Vienna). 2018 Sep;125(9):1361-1372. doi: 10.1007/s00702-018-1891-3. Epub 2018 Jun 1. PMID: 29858658; PMCID: PMC7613147.
  214. Jacobson SA, Morshed T, Dugger BN, Beach TG, Hentz JG, Adler CH, Shill HA, Sabbagh MN, Belden CM, Sue LI, Caviness JN, Hu C; Arizona Parkinson's Disease Consortium. Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations. Parkinsonism Relat Disord. 2014 Sep;20(9):1009-14. doi: 10.1016/j.parkreldis.2014.06.018. Epub 2014 Jun 28. PMID: 25027359; PMCID: PMC4143433.
  215. Lenka A, Ingalhalikar M, Shah A, Saini J, Arumugham SS, Hegde S, George L, Yadav R, Pal PK. Abnormalities in the white matter tracts in patients with Parkinson disease and psychosis. Neurology. 2020 May 5;94(18):e1876-e1884. doi: 10.1212/WNL.0000000000009363. Epub 2020 Apr 21. PMID: 32317347; PMCID: PMC7613151.
  216. Fox SH, Visanji NP, Johnston TH, Gomez-Ramirez J, Voon V, Brotchie JM. Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease. Arch Neurol. 2006 Sep;63(9):1343-4. doi: 10.1001/archneur.63.9.1343. PMID: 16966523.
  217. Goetz CG, Pappert EJ, Blasucci LM, Stebbins GT, Ling ZD, Nora MV, Carvey PM. Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations. Neurology. 1998 Feb;50(2):515-7. doi: 10.1212/wnl.50.2.515. PMID: 9484386.
  218. Dotchin CL, Jusabani A, Walker RW. Non-motor symptoms in a prevalent population with Parkinson's disease in Tanzania. Parkinsonism Relat Disord. 2009 Jul;15(6):457-60. doi: 10.1016/j.parkreldis.2008.11.013. Epub 2009 Feb 3. PMID: 19196538.
  219. de la Riva P, Smith K, Xie SX, Weintraub D. Course of psychiatric symptoms and global cognition in early Parkinson disease. Neurology. 2014 Sep 16;83(12):1096-103. doi: 10.1212/WNL.0000000000000801. Epub 2014 Aug 15. PMID: 25128183; PMCID: PMC4166362.
  220. Weintraub D, Simuni T, Caspell-Garcia C, Coffey C, Lasch S, Siderowf A, Aarsland D, Barone P, Burn D, Chahine LM, Eberling J, Espay AJ, Foster ED, Leverenz JB, Litvan I, Richard I, Troyer MD, Hawkins KA; Parkinson's Progression Markers Initiative. Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. Mov Disord. 2015 Jun;30(7):919-27. doi: 10.1002/mds.26170. Epub 2015 Mar 4. PMID: 25737166; PMCID: PMC4855523.
  221. Goetz CG, Tanner CM, Klawans HL. Pharmacology of hallucinations induced by long-term drug therapy. Am J Psychiatry. 1982 Apr;139(4):494-7. doi: 10.1176/ajp.139.4.494. PMID: 6802003.
  222. Hisahara S, Shimohama S. Dopamine receptors and Parkinson's disease. Int J Med Chem. 2011;2011:403039. doi: 10.1155/2011/403039. Epub 2011 Jun 13. PMID: 25954517; PMCID: PMC4411877.
  223. Moskovitz C, Moses H 3rd, Klawans HL. Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry. 1978 Jun;135(6):669-75. doi: 10.1176/ajp.135.6.669. PMID: 655276.
  224. Sokoloff P, Diaz J, Le Foll B, Guillin O, Leriche L, Bezard E, Gross C. The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets. 2006 Feb;5(1):25-43. doi: 10.2174/187152706784111551. PMID: 16613552.
  225. Rondou P, Haegeman G, Van Craenenbroeck K. The dopamine D4 receptor: biochemical and signalling properties. Cell Mol Life Sci. 2010 Jun;67(12):1971-86. doi: 10.1007/s00018-010-0293-y. Epub 2010 Feb 18. PMID: 20165900.
  226. Schwartz JC, Diaz J, Pilon C, Sokoloff P. Possible implications of the dopamine D(3) receptor in schizophrenia and in antipsychotic drug actions. Brain Res Brain Res Rev. 2000 Mar;31(2-3):277-87. doi: 10.1016/s0165-0173(99)00043-0. PMID: 10719154.
  227. Maramai S, Gemma S, Brogi S, Campiani G, Butini S, Stark H, Brindisi M. Dopamine D3 Receptor Antagonists as Potential Therapeutics for the Treatment of Neurological Diseases. Front Neurosci. 2016 Oct 5;10:451. doi: 10.3389/fnins.2016.00451. PMID: 27761108; PMCID: PMC5050208.
  228. Gurevich EV, Joyce JN. Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons. Neuropsychopharmacology. 1999 Jan;20(1):60-80. doi: 10.1016/S0893-133X(98)00066-9. PMID: 9885786.
  229. Guma E, Rocchetti J, Devenyi GA, Tanti A, Mathieu AP, Lerch JP, Elgbeili G, Courcot B, Mechawar N, Chakravarty MM, Giros B. Role of D3 dopamine receptors in modulating neuroanatomical changes in response to antipsychotic administration. Sci Rep. 2019 May 24;9(1):7850. doi: 10.1038/s41598-019-43955-4. PMID: 31127135; PMCID: PMC6534671.
  230. Yang P, Perlmutter JS, Benzinger TLS, Morris JC, Xu J. Dopamine D3 receptor: A neglected participant in Parkinson Disease pathogenesis and treatment? Ageing Res Rev. 2020 Jan;57:100994. doi: 10.1016/j.arr.2019.100994. Epub 2019 Nov 22. PMID: 31765822; PMCID: PMC6939386.
  231. Bono F, Mutti V, Fiorentini C, Missale C. Dopamine D3 Receptor Heteromerization: Implications for Neuroplasticity and Neuroprotection. Biomolecules. 2020 Jul 9;10(7):1016. doi: 10.3390/biom10071016. PMID: 32659920; PMCID: PMC7407647.
  232. Rossi M, Fasciani I, Marampon F, Maggio R, Scarselli M. The First Negative Allosteric Modulator for Dopamine D2and D3Receptors, SB269652 May Lead to a New Generation of Antipsychotic Drugs. Mol Pharmacol. 2017 Jun;91(6):586-594. doi: 10.1124/mol.116.107607. Epub 2017 Mar 6. PMID: 28265019; PMCID: PMC5438131.
  233. Glickstein SB, Desteno DA, Hof PR, Schmauss C. Mice lacking dopamine D2 and D3 receptors exhibit differential activation of prefrontal cortical neurons during tasks requiring attention. Cereb Cortex. 2005 Jul;15(7):1016-24. doi: 10.1093/cercor/bhh202. Epub 2004 Nov 10. PMID: 15537671.
  234. Sun J, Cairns NJ, Perlmutter JS, Mach RH, Xu J. Regulation of dopamine D₃ receptor in the striatal regions and substantia nigra in diffuse Lewy body disease. Neuroscience. 2013 Sep 17;248:112-26. doi: 10.1016/j.neuroscience.2013.05.048. Epub 2013 Jun 1. PMID: 23732230; PMCID: PMC3796121.
  235. Gomperts SN. Lewy Body Dementias: Dementia With Lewy Bodies and Parkinson Disease Dementia. Continuum (Minneap Minn). 2016 Apr;22(2 Dementia):435-63. doi: 10.1212/CON.0000000000000309. PMID: 27042903; PMCID: PMC5390937.
  236. Jellinger KA, Korczyn AD. Are dementia with Lewy bodies and Parkinson's disease dementia the same disease? BMC Med. 2018 Mar 6;16(1):34. doi: 10.1186/s12916-018-1016-8. PMID: 29510692; PMCID: PMC5840831.
  237. Hepp DH, Ruiter AM, Galis Y, Voorn P, Rozemuller AJ, Berendse HW, Foncke EM, van de Berg WD. Pedunculopontine cholinergic cell loss in hallucinating Parkinson disease patients but not in dementia with Lewy bodies patients. J Neuropathol Exp Neurol. 2013 Dec;72(12):1162-70. doi: 10.1097/NEN.0000000000000014. PMID: 24226265.
  238. Gallagher DA, Parkkinen L, O'Sullivan SS, Spratt A, Shah A, Davey CC, Bremner FD, Revesz T, Williams DR, Lees AJ, Schrag A. Testing an aetiological model of visual hallucinations in Parkinson's disease. Brain. 2011 Nov;134(Pt 11):3299-309. doi: 10.1093/brain/awr225. Epub 2011 Sep 15. PMID: 21921019.
  239. Fischer NM, Hinkle JT, Perepezko K, Bakker CC, Morris M, Broen MPG, Butala A, Dawson TM, Leentjens AFG, Mari Z, Marvel CL, Mills KA, Rosenthal LS, Shepard MD, Pantelyat A, Bakker A, Pletnikova O, Troncoso JC, Wang J, Pontone GM. Brainstem Pathologies Correlate With Depression and Psychosis in Parkinson's Disease. Am J Geriatr Psychiatry. 2021 Sep;29(9):958-968. doi: 10.1016/j.jagp.2020.12.009. Epub 2021 Jan 15. PMID: 33455856; PMCID: PMC8277871.
  240. Arnulf I, Bonnet AM, Damier P, Bejjani BP, Seilhean D, Derenne JP, Agid Y. Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis. Neurology. 2000 Jul 25;55(2):281-8. doi: 10.1212/wnl.55.2.281. PMID: 10908906.
  241. Barnes J, Boubert L, Harris J, Lee A, David AS. Reality monitoring and visual hallucinations in Parkinson's disease. Neuropsychologia. 2003;41(5):565-74. doi: 10.1016/s0028-3932(02)00182-3. PMID: 12559149.
  242. Diederich NJ, Goetz CG, Stebbins GT. Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: focused review and a new integrative model. Mov Disord. 2005 Feb;20(2):130-40. doi: 10.1002/mds.20308. PMID: 15486924.
  243. Grossi D, Trojano L, Pellecchia MT, Amboni M, Fragassi NA, Barone P. Frontal dysfunction contributes to the genesis of hallucinations in non-demented Parkinsonian patients. Int J Geriatr Psychiatry. 2005 Jul;20(7):668-73. doi: 10.1002/gps.1339. PMID: 16021658.
  244. Shine JM, Halliday GM, Naismith SL, Lewis SJ. Visual misperceptions and hallucinations in Parkinson's disease: dysfunction of attentional control networks? Mov Disord. 2011 Oct;26(12):2154-9. doi: 10.1002/mds.23896. Epub 2011 Sep 23. PMID: 21953814.
  245. Stebbins GT, Goetz CG, Carrillo MC, Bangen KJ, Turner DA, Glover GH, Gabrieli JD. Altered cortical visual processing in PD with hallucinations: an fMRI study. Neurology. 2004 Oct 26;63(8):1409-16. doi: 10.1212/01.wnl.0000141853.27081.bd. PMID: 15505157.
  246. Meppelink AM, de Jong BM, Renken R, Leenders KL, Cornelissen FW, van Laar T. Impaired visual processing preceding image recognition in Parkinson's disease patients with visual hallucinations. Brain. 2009 Nov;132(Pt 11):2980-93. doi: 10.1093/brain/awp223. Epub 2009 Sep 15. PMID: 19755518.
  247. Straughan S, Collerton D, Bruce V. Visual Priming and Visual Hallucinations in Parkinson's Disease. Evidence for Normal Top-Down Processes. J Geriatr Psychiatry Neurol. 2016 Jan;29(1):25-30. doi: 10.1177/0891988715598237. Epub 2015 Jul 30. PMID: 26232406.
  248. Firbank MJ, Parikh J, Murphy N, Killen A, Allan CL, Collerton D, Blamire AM, Taylor JP. Reduced occipital GABA in Parkinson disease with visual hallucinations. Neurology. 2018 Aug 14;91(7):e675-e685. doi: 10.1212/WNL.0000000000006007. Epub 2018 Jul 18. PMID: 30021920; PMCID: PMC6105043.
  249. Bejr-Kasem H, Sampedro F, Marín-Lahoz J, Martínez-Horta S, Pagonabarraga J, Kulisevsky J. Minor hallucinations reflect early gray matter loss and predict subjective cognitive decline in Parkinson's disease. Eur J Neurol. 2021 Feb;28(2):438-447. doi: 10.1111/ene.14576. Epub 2020 Nov 5. PMID: 33032389.
  250. Goldman JG, Stebbins GT, Dinh V, Bernard B, Merkitch D, deToledo-Morrell L, Goetz CG. Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson's disease with hallucinations. Brain. 2014 Mar;137(Pt 3):849-59. doi: 10.1093/brain/awt360. Epub 2014 Jan 29. PMID: 24480486; PMCID: PMC3983409.
  251. Zarkali A, McColgan P, Leyland LA, Lees AJ, Rees G, Weil RS. Fiber-specific white matter reductions in Parkinson hallucinations and visual dysfunction. Neurology. 2020 Apr 7;94(14):e1525-e1538. doi: 10.1212/WNL.0000000000009014. Epub 2020 Feb 24. PMID: 32094242; PMCID: PMC7251523.
  252. Chen CC, Lee ST, Wu T, Chen CJ, Chen MC, Lu CS. Short-term effect of bilateral subthalamic stimulation for advanced Parkinson's disease. Chang Gung Med J. 2003 May;26(5):344-51. PMID: 12934851.
  253. Khan NL, Graham E, Critchley P, Schrag AE, Wood NW, Lees AJ, Bhatia KP, Quinn N. Parkin disease: a phenotypic study of a large case series. Brain. 2003 Jun;126(Pt 6):1279-92. doi: 10.1093/brain/awg142. PMID: 12764051.
  254. Lohmann E, Thobois S, Lesage S, Broussolle E, du Montcel ST, Ribeiro MJ, Remy P, Pelissolo A, Dubois B, Mallet L, Pollak P, Agid Y, Brice A; French Parkinson's Disease Genetics Study Group. A multidisciplinary study of patients with early-onset PD with and without parkin mutations. Neurology. 2009 Jan 13;72(2):110-6. doi: 10.1212/01.wnl.0000327098.86861.d4. Epub 2008 Nov 5. PMID: 18987353; PMCID: PMC2677494.
  255. Ross OA, Braithwaite AT, Skipper LM, Kachergus J, Hulihan MM, Middleton FA, Nishioka K, Fuchs J, Gasser T, Maraganore DM, Adler CH, Larvor L, Chartier-Harlin MC, Nilsson C, Langston JW, Gwinn K, Hattori N, Farrer MJ. Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann Neurol. 2008 Jun;63(6):743-50. doi: 10.1002/ana.21380. PMID: 18571778; PMCID: PMC3850281.
  256. Nishioka K, Hayashi S, Farrer MJ, Singleton AB, Yoshino H, Imai H, Kitami T, Sato K, Kuroda R, Tomiyama H, Mizoguchi K, Murata M, Toda T, Imoto I, Inazawa J, Mizuno Y, Hattori N. Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. Ann Neurol. 2006 Feb;59(2):298-309. doi: 10.1002/ana.20753. PMID: 16358335.
  257. Oeda T, Umemura A, Mori Y, Tomita S, Kohsaka M, Park K, Inoue K, Fujimura H, Hasegawa H, Sugiyama H, Sawada H. Impact of glucocerebrosidase mutations on motor and nonmotor complications in Parkinson's disease. Neurobiol Aging. 2015 Dec;36(12):3306-3313. doi: 10.1016/j.neurobiolaging.2015.08.027. Epub 2015 Sep 7. PMID: 26422360.
  258. Lenka A, Arumugham SS, Christopher R, Pal PK. Genetic substrates of psychosis in patients with Parkinson's disease: A critical review. J Neurol Sci. 2016 May 15;364:33-41. doi: 10.1016/j.jns.2016.03.005. Epub 2016 Mar 3. PMID: 27084212.
  259. Ojo OO, Fernandez HH. Current Understanding of Psychosis in Parkinson's Disease. Curr Psychiatry Rep. 2016 Oct;18(10):97. doi: 10.1007/s11920-016-0730-1. PMID: 27629356.
  260. de la Fuente-Fernández R, Núñez MA, López E. The apolipoprotein E epsilon 4 allele increases the risk of drug-induced hallucinations in Parkinson's disease. Clin Neuropharmacol. 1999 Jul-Aug;22(4):226-30. PMID: 10442253.
  261. Factor SA, Steenland NK, Higgins DS, Molho ES, Kay DM, Montimurro J, Rosen AR, Zabetian CP, Payami H. Disease-related and genetic correlates of psychotic symptoms in Parkinson's disease. Mov Disord. 2011 Oct;26(12):2190-5. doi: 10.1002/mds.23806. Epub 2011 Jun 28. PMID: 21714002; PMCID: PMC4216677.
  262. Goetz CG, Burke PF, Leurgans S, Berry-Kravis E, Blasucci LM, Raman R, Zhou L. Genetic variation analysis in parkinson disease patients with and without hallucinations: case-control study. Arch Neurol. 2001 Feb;58(2):209-13. doi: 10.1001/archneur.58.2.209. PMID: 11176958.
  263. Camicioli R, Rajput A, Rajput M, Reece C, Payami H, Hao C, Rajput A. Apolipoprotein E epsilon4 and catechol-O-methyltransferase alleles in autopsy-proven Parkinson's disease: relationship to dementia and hallucinations. Mov Disord. 2005 Aug;20(8):989-94. doi: 10.1002/mds.20481. PMID: 15852364.
  264. Papapetropoulos S, Farrer MJ, Stone JT, Milkovic NM, Ross OA, Calvo L, McQuorquodale D, Mash DC. Phenotypic associations of tau and ApoE in Parkinson's disease. Neurosci Lett. 2007 Mar 6;414(2):141-4. doi: 10.1016/j.neulet.2006.12.008. Epub 2007 Jan 3. PMID: 17204369.
  265. Feldman B, Chapman J, Korczyn AD. Apolipoprotein epsilon4 advances appearance of psychosis in patients with Parkinson's disease. Acta Neurol Scand. 2006 Jan;113(1):14-7. doi: 10.1111/j.1600-0404.2005.00535.x. PMID: 16367893.
  266. Monsell SE, Besser LM, Heller KB, Checkoway H, Litvan I, Kukull WA. Clinical and pathologic presentation in Parkinson's disease by apolipoprotein e4 allele status. Parkinsonism Relat Disord. 2014 May;20(5):503-7. doi: 10.1016/j.parkreldis.2014.02.001. Epub 2014 Feb 13. PMID: 24582705; PMCID: PMC4028373.
  267. Vaughan RA, Foster JD. Mechanisms of dopamine transporter regulation in normal and disease states. Trends Pharmacol Sci. 2013 Sep;34(9):489-96. doi: 10.1016/j.tips.2013.07.005. Epub 2013 Aug 20. PMID: 23968642; PMCID: PMC3831354.
  268. Kim JW, Kim DH, Kim SH, Cha JK. Association of the dopamine transporter gene with Parkinson's disease in Korean patients. J Korean Med Sci. 2000 Aug;15(4):449-51. doi: 10.3346/jkms.2000.15.4.449. PMID: 10983695; PMCID: PMC3054662.
  269. Wang J, Liu Z, Chen B. [Association between genetic polymorphism of dopamine transporter gene and susceptibility to Parkinson's disease]. Zhonghua Yi Xue Za Zhi. 2000 May;80(5):346-8. Chinese. PMID: 11798784.
  270. Le Couteur DG, Leighton PW, McCann SJ, Pond Sm. Association of a polymorphism in the dopamine-transporter gene with Parkinson's disease. Mov Disord. 1997 Sep;12(5):760-3. doi: 10.1002/mds.870120523. PMID: 9380062.
  271. Kaiser R, Hofer A, Grapengiesser A, Gasser T, Kupsch A, Roots I, Brockmöller J. L -dopa-induced adverse effects in PD and dopamine transporter gene polymorphism. Neurology. 2003 Jun 10;60(11):1750-5. doi: 10.1212/01.wnl.0000068009.32067.a1. PMID: 12796525.
  272. Radojević B, Dragašević-Mišković NT, Marjanović A, Branković M, Dobričić V, Milovanović A, Tomić A, Svetel M, Petrović I, Jančić I, Stanisavljević D, Savić MM, Kostić VS. Clinical and Genetic Analysis of Psychosis in Parkinson's Disease. J Parkinsons Dis. 2021;11(4):1973-1980. doi: 10.3233/JPD-212716. PMID: 34151861.
  273. Schumacher-Schuh AF, Francisconi C, Altmann V, Monte TL, Callegari-Jacques SM, Rieder CR, Hutz MH. Polymorphisms in the dopamine transporter gene are associated with visual hallucinations and levodopa equivalent dose in Brazilians with Parkinson's disease. Int J Neuropsychopharmacol. 2013 Jul;16(6):1251-1258. doi: 10.1017/S1461145712001666. Epub 2013 Jan 30. PMID: 23363854.
  274. Wang J, Zhao C, Chen B, Liu ZL. Polymorphisms of dopamine receptor and transporter genes and hallucinations in Parkinson's disease. Neurosci Lett. 2004 Jan 30;355(3):193-6. doi: 10.1016/j.neulet.2003.11.006. Erratum in: Neurosci Lett. 2004 Aug 5;366(1):112. PMID: 14732464.
  275. Damasceno Dos Santos EU, Duarte EBC, Miranda LMR, Asano AGC, Asano NMJ, Maia MMD, de Souza PRE. Pharmacogenetic Profile and the Occurrence of Visual Hallucinations in Patients With Sporadic Parkinson's Disease. J Clin Pharmacol. 2019 Jul;59(7):1006-1013. doi: 10.1002/jcph.1394. Epub 2019 Feb 22. PMID: 30794329.
  276. Redenšek S, Flisar D, Kojović M, Gregorič Kramberger M, Georgiev D, Pirtošek Z, Trošt M, Dolžan V. Dopaminergic Pathway Genes Influence Adverse Events Related to Dopaminergic Treatment in Parkinson's Disease. Front Pharmacol. 2019 Jan 28;10:8. doi: 10.3389/fphar.2019.00008. PMID: 30745869; PMCID: PMC6360186.
  277. Makoff AJ, Graham JM, Arranz MJ, Forsyth J, Li T, Aitchison KJ, Shaikh S, Grünewald RA. Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson's disease. Pharmacogenetics. 2000 Feb;10(1):43-8. doi: 10.1097/00008571-200002000-00006. PMID: 10739171.
  278. Fujii C, Harada S, Ohkoshi N, Hayashi A, Yoshizawa K, Ishizuka C, Nakamura T. Association between polymorphism of the cholecystokinin gene and idiopathic Parkinson's disease. Clin Genet. 1999 Nov;56(5):394-9. doi: 10.1034/j.1399-0004.1999.560508.x. PMID: 10668930.
  279. Wang J, Si YM, Liu ZL, Yu L. Cholecystokinin, cholecystokinin-A receptor and cholecystokinin-B receptor gene polymorphisms in Parkinson's disease. Pharmacogenetics. 2003 Jun;13(6):365-9. doi: 10.1097/00008571-200306000-00008. PMID: 12777967.
  280. Goldman JG, Goetz CG, Berry-Kravis E, Leurgans S, Zhou L. Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: an analysis of the cholecystokinin system. Arch Neurol. 2004 Aug;61(8):1280-4. doi: 10.1001/archneur.61.8.1280. PMID: 15313848.
  281. Goldman JG, Marr D, Zhou L, Ouyang B, Leurgans SE, Berry-Kravis E, Goetz CG. Racial differences may influence the role of cholecystokinin polymorphisms in Parkinson's disease hallucinations. Mov Disord. 2011 Aug 1;26(9):1781-2. doi: 10.1002/mds.23655. Epub 2011 Apr 19. PMID: 21506165; PMCID: PMC3142314.
  282. De Luca V, Annesi G, De Marco EV, de Bartolomeis A, Nicoletti G, Pugliese P, Muscettola G, Barone P, Quattrone A. HOMER1 promoter analysis in Parkinson's disease: association study with psychotic symptoms. Neuropsychobiology. 2009;59(4):239-45. doi: 10.1159/000230689. Epub 2009 Jul 31. PMID: 19648775.
  283. Schumacher-Schuh AF, Altmann V, Rieck M, Tovo-Rodrigues L, Monte TL, Callegari-Jacques SM, Medeiros MS, Rieder CR, Hutz MH. Association of common genetic variants of HOMER1 gene with levodopa adverse effects in Parkinson's disease patients. Pharmacogenomics J. 2014 Jun;14(3):289-94. doi: 10.1038/tpj.2013.37. Epub 2013 Oct 15. PMID: 24126708.
  284. Lin JJ, Yueh KC, Lin SZ, Harn HJ, Liu JT. Genetic polymorphism of the angiotensin converting enzyme and L-dopa-induced adverse effects in Parkinson's disease. J Neurol Sci. 2007 Jan 31;252(2):130-4. doi: 10.1016/j.jns.2006.10.018. Epub 2006 Dec 28. PMID: 17196621.
  285. Pascale E, Purcaro C, Passarelli E, Guglielmi R, Vestri AR, Passarelli F, Meco G. Genetic polymorphism of Angiotensin-Converting Enzyme is not associated with the development of Parkinson's disease and of L-dopa-induced adverse effects. J Neurol Sci. 2009 Jan 15;276(1-2):18-21. doi: 10.1016/j.jns.2008.08.017. Epub 2008 Sep 20. PMID: 18805557.
  286. Pérez-Santamarina E, García-Ruiz P, Martínez-Rubio D, Ezquerra M, Pla-Navarro I, Puente J, Martí MJ, Palau F, Hoenicka J. Regulatory rare variants of the dopaminergic gene ANKK1 as potential risk factors for Parkinson's disease. Sci Rep. 2021 May 10;11(1):9879. doi: 10.1038/s41598-021-89300-6. Erratum in: Sci Rep. 2022 Jul 26;12(1):12719. PMID: 33972609; PMCID: PMC8110570.
  287. Weintraub D, Aarsland D, Chaudhuri KR, Dobkin RD, Leentjens AF, Rodriguez-Violante M, Schrag A. The neuropsychiatry of Parkinson's disease: advances and challenges. Lancet Neurol. 2022 Jan;21(1):89-102. doi: 10.1016/S1474-4422(21)00330-6. PMID: 34942142; PMCID: PMC8800169.
  288. Creese B, Ballard C, Aarsland D, Londos E, Sharp S, Jones E. Determining the association of the 5HTTLPR polymorphism with delusions and hallucinations in Lewy body dementias. Am J Geriatr Psychiatry. 2014 Jun;22(6):580-6. doi: 10.1016/j.jagp.2012.11.001. Epub 2013 Apr 9. PMID: 23582751.
  289. Sawada H, Oeda T, Umemura A, Tomita S, Hayashi R, Kohsaka M, Yamamoto K, Sudoh S, Sugiyama H. Subclinical elevation of plasma C-reactive protein and illusions/hallucinations in subjects with Parkinson's disease: case-control study. PLoS One. 2014 Jan 31;9(1):e85886. doi: 10.1371/journal.pone.0085886. PMID: 24497930; PMCID: PMC3908859.
  290. Redenšek S, Jenko Bizjan B, Trošt M, Dolžan V. Clinical and Clinical-Pharmacogenetic Models for Prediction of the Most Common Psychiatric Complications Due to Dopaminergic Treatment in Parkinson's Disease. Int J Neuropsychopharmacol. 2020 Nov 26;23(8):496-504. doi: 10.1093/ijnp/pyaa028. PMID: 32710539; PMCID: PMC7689202.
  291. Gao L, Díaz-Corrales FJ, Carrillo F, Díaz-Martín J, Caceres-Redondo MT, Carballo M, Palomino A, López-Barneo J, Mir P. Brain-derived neurotrophic factor G196A polymorphism and clinical features in Parkinson's disease. Acta Neurol Scand. 2010 Jul;122(1):41-5. doi: 10.1111/j.1600-0404.2009.01253.x. Epub 2010 Jan 19. PMID: 20085561.
  292. Ramezani M, Ruskey JA, Martens K, Kibreab M, Javer Z, Kathol I, Hammer T, Cheetham J, Leveille E, Martino D, Sarna JR, Gan-Or Z, Pfeffer G, Ismail Z, Monchi O. Association Between BDNF Val66Met Polymorphism and Mild Behavioral Impairment in Patients With Parkinson's Disease. Front Neurol. 2021 Jan 14;11:587992. doi: 10.3389/fneur.2020.587992. PMID: 33584494; PMCID: PMC7874164.
  293. Gordon PC, Rocha MS, Kauark RG, Costa CD, de Oliveira MO, Godinho F, Borges V. Validation of the National Institute of Neurological Disorders and Stroke Criteria for Psychosis in Parkinson Disease. Am J Geriatr Psychiatry. 2017 Jan;25(1):73-80. doi: 10.1016/j.jagp.2016.08.011. Epub 2016 Aug 26. PMID: 27742525.
  294. Sahoo S, Grover S. Psychotic symptoms in patients with Parkinson's disease: A case report and overview of management. J Geriatr Ment Health. 2017; 4:58-63
  295. Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F, Odin P, Ondo W, Abe K, Macphee G, Macmahon D, Barone P, Rabey M, Forbes A, Breen K, Tluk S, Naidu Y, Olanow W, Williams AJ, Thomas S, Rye D, Tsuboi Y, Hand A, Schapira AH. The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study. Mov Disord. 2007 Oct 15;22(13):1901-11. doi: 10.1002/mds.21596. PMID: 17674410.
  296. Goetz CG, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stebbins GT, Stern MB, Tilley BC, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, Van Hilten JJ, LaPelle N. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord. 2007 Jan;22(1):41-7. doi: 10.1002/mds.21198. PMID: 17115387.
  297. Sawada H, Oeda T. Protocol for a randomised controlled trial: efficacy of donepezil against psychosis in Parkinson's disease (EDAP). BMJ Open. 2013 Sep 25;3(9):e003533. doi: 10.1136/bmjopen-2013-003533. Erratum in: BMJ Open. 2016 Sep 02;6(9):e003533corr1. PMID: 24071461; PMCID: PMC3787472.
  298. Voss T, Bahr D, Cummings J, Mills R, Ravina B, Williams H. Performance of a shortened Scale for Assessment of Positive Symptoms for Parkinson's disease psychosis. Parkinsonism Relat Disord. 2013 Mar;19(3):295-9. doi: 10.1016/j.parkreldis.2012.10.022. Epub 2012 Dec 1. PMID: 23211417.
  299. Rodríguez-Violante M, Cervantes-Arriaga A, Velázquez-Osuna S, Llorens-Arenas R, Calderón-Fajardo H, Piña-Fuentes D, Martinez-Martin P. Independent Validation of the SEND-PD and Correlation with the MDS-UPDRS Part IA. Parkinsons Dis. 2014;2014:260485. doi: 10.1155/2014/260485. Epub 2014 Oct 23. PMID: 25400976; PMCID: PMC4226183.
  300. Mosley PE, Moodie R, Dissanayaka N. Caregiver Burden in Parkinson Disease: A Critical Review of Recent Literature. J Geriatr Psychiatry Neurol. 2017 Sep;30(5):235-252. doi: 10.1177/0891988717720302. Epub 2017 Jul 26. PMID: 28743212.
  301. Adelman RD, Tmanova LL, Delgado D, Dion S, Lachs MS. Caregiver burden: a clinical review. JAMA. 2014 Mar 12;311(10):1052-60. doi: 10.1001/jama.2014.304. PMID: 24618967.
  302. Friedman JH. Parkinson disease psychosis: Update. Behav Neurol. 2013 Jan 1;27(4):469-77. doi: 10.3233/BEN-129016. PMID: 23242358; PMCID: PMC5214983.
  303. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology. 2001 Jun;56(11 Suppl 5):S1-S88. doi: 10.1212/wnl.56.suppl_5.s1. PMID: 11402154.
  304. Thomsen TR, Panisset M, Suchowersky O, Goodridge A, Mendis T, Lang AE. Impact of standard of care for psychosis in Parkinson disease. J Neurol Neurosurg Psychiatry. 2008 Dec;79(12):1413-5. doi: 10.1136/jnnp.2008.153163. PMID: 19010958.
  305. Factor SA, Molho ES, Friedman JH. Risperidone and Parkinson's disease. Mov Disord. 2002 Jan;17(1):221-2. doi: 10.1002/mds.1258. PMID: 11835472.
  306. Ford B, Lynch T, Greene P. Risperidone in Parkinson's disease. Lancet. 1994 Sep 3;344(8923):681. doi: 10.1016/s0140-6736(94)92114-8. PMID: 7520964.
  307. Breier A, Sutton VK, Feldman PD, Kadam DL, Ferchland I, Wright P, Friedman JH. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biol Psychiatry. 2002 Sep 1;52(5):438-45. doi: 10.1016/s0006-3223(02)01392-6. PMID: 12242060.
  308. Ondo WG, Levy JK, Vuong KD, Hunter C, Jankovic J. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord. 2002 Sep;17(5):1031-5. doi: 10.1002/mds.10217. PMID: 12360554.
  309. Pintor L, Valldeoriola F, Baillés E, Martí MJ, Muñiz A, Tolosa E. Ziprasidone versus clozapine in the treatment of psychotic symptoms in Parkinson disease: a randomized open clinical trial. Clin Neuropharmacol. 2012 Mar-Apr;35(2):61-6. doi: 10.1097/WNF.0b013e31824d5115. PMID: 22388466.
  310. Schindehütte J, Trenkwalder C. Treatment of drug-induced psychosis in Parkinson's disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing. Clin Neurol Neurosurg. 2007 Feb;109(2):188-91. doi: 10.1016/j.clineuro.2006.07.003. Epub 2006 Sep 1. PMID: 16949733.
  311. Fernandez HH, Trieschmann ME, Friedman JH. Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience. Clin Neuropharmacol. 2004 Jan-Feb;27(1):4-5. doi: 10.1097/00002826-200401000-00003. PMID: 15090928.
  312. Kwan, C., Frouni, I., Huot, P. (2021). Pharmacotherapy of Psychosis in Parkinson’s Disease. In: Riederer, P., Laux, G., Nagatsu, T., Le, W., Riederer, C. (eds) NeuroPsychopharmacotherapy. Springer, Cham. https://doi.org/10.1007/978-3-319-56015-1_439-1
  313. FDA Public Health Advisory. Deaths with antipsychotics in elderlypatients with behavioral disturbances. http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationfor patients and providers/ucm053171. Accessed 11 April 2005.
  314. Trifirò G, Verhamme KM, Ziere G, Caputi AP, Ch Stricker BH, Sturkenboom MC. All-cause mortality associated with atypical and typical antipsychotics in demented outpatients. Pharmacoepidemiol Drug Saf. 2007 May;16(5):538-44. doi: 10.1002/pds.1334. PMID: 17036366.
  315. Wu CS, Tsai YT, Tsai HJ. Antipsychotic drugs and the risk of ventricular arrhythmia and/or sudden cardiac death: a nation-wide case-crossover study. J Am Heart Assoc. 2015 Feb 23;4(2):e001568. doi: 10.1161/JAHA.114.001568. PMID: 25713294; PMCID: PMC4345877.
  316. McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, Dickson D, Dubois B, Duda JE, Feldman H, Gauthier S, Halliday G, Lawlor B, Lippa C, Lopez OL, Carlos Machado J, O'Brien J, Playfer J, Reid W; International Psychogeriatric Association Expert Meeting on DLB. Dementia with Lewy bodies. Lancet Neurol. 2004 Jan;3(1):19-28. doi: 10.1016/s1474-4422(03)00619-7. PMID: 14693108.
  317. Forsaa EB, Larsen JP, Wentzel-Larsen T, Alves G. What predicts mortality in Parkinson disease?: a prospective population-based long-term study. Neurology. 2010 Oct 5;75(14):1270-6. doi: 10.1212/WNL.0b013e3181f61311. PMID: 20921512.
  318. Badcock JC, Larøi F, Kamp K, Kelsall-Foreman I, Bucks RS, Weinborn M, Begemann M, Taylor JP, Collerton D, O'Brien JT, El Haj M, Ffytche D, Sommer IE. Hallucinations in Older Adults: A Practical Review. Schizophr Bull. 2020 Dec 1;46(6):1382-1395. doi: 10.1093/schbul/sbaa073. PMID: 32638012; PMCID: PMC7707075.
  319. Sanagawa A, Shiraishi N, Sekiguchi F, Akechi T, Kimura K. Successful Use of Brexpiprazole for Parkinson's Disease Psychosis Without Adverse Effects: A Case Report. J Clin Psychopharmacol. 2019 Nov/Dec;39(6):685-687. doi: 10.1097/JCP.0000000000001127. PMID: 31688389.
  320. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009 Jan 3;373(9657):31-41. doi: 10.1016/S0140-6736(08)61764-X. Epub 2008 Dec 6. PMID: 19058842.
  321. Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med. 1999 Mar 11;340(10):757-63. doi: 10.1056/NEJM199903113401003. PMID: 10072410.
  322. Clozapine in drug-induced psychosis in Parkinson's disease. The French Clozapine Parkinson Study Group. Lancet. 1999 Jun 12;353(9169):2041-2. PMID: 10376627.
  323. Miyasaki JM, Shannon K, Voon V, Ravina B, Kleiner-Fisman G, Anderson K, Shulman LM, Gronseth G, Weiner WJ; Quality Standards Subcommittee of the American Academy of Neurology. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006 Apr 11;66(7):996-1002. doi: 10.1212/01.wnl.0000215428.46057.3d. PMID: 16606910.
  324. Frieling H, Hillemacher T, Ziegenbein M, Neundörfer B, Bleich S. Treating dopamimetic psychosis in Parkinson's disease: structured review and meta-analysis. Eur Neuropsychopharmacol. 2007 Feb;17(3):165-71. doi: 10.1016/j.euroneuro.2006.08.007. Epub 2006 Oct 27. PMID: 17070675.
  325. Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, Hametner EM, Poewe W, Rascol O, Goetz CG, Sampaio C. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord. 2011 Oct;26 Suppl 3(0 3):S42-80. doi: 10.1002/mds.23884. PMID: 22021174; PMCID: PMC4020145.
  326. Kapur S, Seeman P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. J Psychiatry Neurosci. 2000 Mar;25(2):161-6. PMID: 10740989; PMCID: PMC1408069.
  327. Kessler RM, Ansari MS, Riccardi P, Li R, Jayathilake K, Dawant B, Meltzer HY. Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine. Neuropsychopharmacology. 2006 Sep;31(9):1991-2001. doi: 10.1038/sj.npp.1301108. Epub 2006 May 31. PMID: 16738543.
  328. Honigfeld G, Arellano F, Sethi J, Bianchini A, Schein J. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry. 1998;59 Suppl 3:3-7. PMID: 9541331.
  329. Hack N, Fayad SM, Monari EH, Akbar U, Hardwick A, Rodriguez RL, Malaty IA, Romrell J, Wagle Shukla AA, McFarland N, Ward HE, Okun MS. An eight-year clinic experience with clozapine use in a Parkinson's disease clinic setting. PLoS One. 2014 Mar 19;9(3):e91545. doi: 10.1371/journal.pone.0091545. PMID: 24646688; PMCID: PMC3960134.
  330. Thomas AA, Friedman JH. Current use of clozapine in Parkinson disease and related disorders. Clin Neuropharmacol. 2010 Jan-Feb;33(1):14-6. doi: 10.1097/WNF.0b013e3181c47168. PMID: 20023573.
  331. Haidary HA, Padhy RK. Clozapine. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. https://www.ncbi.nlm.nih.gov/books/NBK535399/
  332. Yuen JWY, Kim DD, Procyshyn RM, White RF, Honer WG, Barr AM. Clozapine-Induced Cardiovascular Side Effects and Autonomic Dysfunction: A Systematic Review. Front Neurosci. 2018 Apr 4;12:203. doi: 10.3389/fnins.2018.00203. PMID: 29670504; PMCID: PMC5893810.
  333. Richelson E. Preclinical pharmacology of neuroleptics: focus on new generation compounds. J Clin Psychiatry. 1996;57 Suppl 11:4-11. PMID: 8941166.
  334. Rabey JM, Prokhorov T, Miniovitz A, Dobronevsky E, Klein C. Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration. Mov Disord. 2007 Feb 15;22(3):313-8. doi: 10.1002/mds.21116. PMID: 17034006.
  335. Shotbolt P, Samuel M, Fox C, David AS. A randomized controlled trial of quetiapine for psychosis in Parkinson's disease. Neuropsychiatr Dis Treat. 2009;5:327-32. doi: 10.2147/ndt.s5335. Epub 2009 Jun 10. PMID: 19557142; PMCID: PMC2699657.
  336. Ondo WG, Tintner R, Voung KD, Lai D, Ringholz G. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord. 2005 Aug;20(8):958-63. doi: 10.1002/mds.20474. PMID: 15800937.
  337. Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzenschlager R, Perez Lloret S, Weintraub D, Sampaio C; the collaborators of the Parkinson's Disease Update on Non-Motor Symptoms Study Group on behalf of the Movement Disorders Society Evidence-Based Medicine Committee. Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review. Mov Disord. 2019 Feb;34(2):180-198. doi: 10.1002/mds.27602. Epub 2019 Jan 17. Erratum in: Mov Disord. 2019 May;34(5):765. PMID: 30653247; PMCID: PMC6916382.
  338. Aarsland D, Emre M, Lees A, Poewe W, Ballard C. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2007 Jan 2;68(1):80; author reply 81. doi: 10.1212/01.wnl.0000252956.34585.a6. PMID: 17200503.
  339. Morgante L, Epifanio A, Spina E, Zappia M, Di Rosa AE, Marconi R, Basile G, Di Raimondo G, La Spina P, Quattrone A. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol. 2004 Jul-Aug;27(4):153-6. doi: 10.1097/01.wnf.0000136891.17006.ec. Erratum in: Clin Neuropharmacol. 2004 Sep-Oct;27(5):256. PMID: 15319699.
  340. Merims D, Balas M, Peretz C, Shabtai H, Giladi N. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis. Clin Neuropharmacol. 2006 Nov-Dec;29(6):331-7. doi: 10.1097/01.WNF.0000236769.31279.19. PMID: 17095896.
  341. Marek GJ, Carpenter LL, McDougle CJ, Price LH. Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. Neuropsychopharmacology. 2003 Feb;28(2):402-12. doi: 10.1038/sj.npp.1300057. Epub 2002 Sep 13. PMID: 12589395.
  342. Hamadjida A, Nuara SG, Gourdon JC, Huot P. The effect of mianserin on the severity of psychosis and dyskinesia in the parkinsonian marmoset. Prog Neuropsychopharmacol Biol Psychiatry. 2018 Feb 2;81:367-371. doi: 10.1016/j.pnpbp.2017.09.001. Epub 2017 Sep 5. PMID: 28882428.
  343. Hamadjida A, Nuara SG, Veyres N, Frouni I, Kwan C, Sid-Otmane L, Harraka MJ, Gourdon JC, Huot P. The effect of mirtazapine on dopaminergic psychosis and dyskinesia in the parkinsonian marmoset. Psychopharmacology (Berl). 2017 Mar;234(6):905-911. doi: 10.1007/s00213-017-4530-z. Epub 2017 Jan 27. PMID: 28130646.
  344. Godschalx-Dekker JA, Siegers HP. Reduction of parkinsonism and psychosis with mirtazapine: a case report. Pharmacopsychiatry. 2014 May;47(3):81-3. doi: 10.1055/s-0034-1367014. Epub 2014 Feb 6. PMID: 24504487.
  345. Tagai K, Nagata T, Shinagawa S, Tsuno N, Ozone M, Nakayama K. Mirtazapine improves visual hallucinations in Parkinson's disease: a case report. Psychogeriatrics. 2013 Jun;13(2):103-7. doi: 10.1111/j.1479-8301.2012.00432.x. PMID: 23909968.
  346. Weiner DM, Burstein ES, Nash N, Croston GE, Currier EA, Vanover KE, Harvey SC, Donohue E, Hansen HC, Andersson CM, Spalding TA, Gibson DF, Krebs-Thomson K, Powell SB, Geyer MA, Hacksell U, Brann MR. 5-hydroxytryptamine2A receptor inverse agonists as antipsychotics. J Pharmacol Exp Ther. 2001 Oct;299(1):268-76. PMID: 11561089.
  347. Huot P. 5-HT2Areceptors and Parkinson's disease psychosis: a pharmacological discussion. Neurodegener Dis Manag. 2018 Dec;8(6):363-365. doi: 10.2217/nmt-2018-0039. Epub 2018 Nov 19. PMID: 30451579.
  348. Vanover KE, Weiner DM, Makhay M, Veinbergs I, Gardell LR, Lameh J, Del Tredici AL, Piu F, Schiffer HH, Ott TR, Burstein ES, Uldam AK, Thygesen MB, Schlienger N, Andersson CM, Son TY, Harvey SC, Powell SB, Geyer MA, Tolf BR, Brann MR, Davis RE. Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist. J Pharmacol Exp Ther. 2006 May;317(2):910-8. doi: 10.1124/jpet.105.097006. Epub 2006 Feb 9. PMID: 16469866.
  349. Meltzer HY, Mills R, Revell S, Williams H, Johnson A, Bahr D, Friedman JH. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis. Neuropsychopharmacology. 2010 Mar;35(4):881-92. doi: 10.1038/npp.2009.176. Epub 2009 Nov 11. PMID: 19907417; PMCID: PMC3055369.
  350. Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, Dhall R, Ballard C. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014 Feb 8;383(9916):533-40. doi: 10.1016/S0140-6736(13)62106-6. Epub 2013 Nov 1. Erratum in: Lancet. 2014 Jul 5;384(9937):28. PMID: 24183563.
  351. Yasue I, Matsunaga S, Kishi T, Fujita K, Iwata N. Serotonin 2A Receptor Inverse Agonist as a Treatment for Parkinson's Disease Psychosis: A Systematic Review and Meta-analysis of Serotonin 2A Receptor Negative Modulators. J Alzheimers Dis. 2016;50(3):733-40. doi: 10.3233/JAD-150818. PMID: 26757194.
  352. Webster P. Pimavanserin evaluated by the FDA. Lancet. 2018 May 5;391(10132):1762. doi: 10.1016/S0140-6736(18)31002-X. PMID: 29739555.
  353. Ballard C, Isaacson S, Mills R, Williams H, Corbett A, Coate B, Pahwa R, Rascol O, Burn DJ. Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis. J Am Med Dir Assoc. 2015 Oct 1;16(10):898.e1-7. doi: 10.1016/j.jamda.2015.06.021. Epub 2015 Aug 1. PMID: 26239690.
  354. Rovers JM, Dautzenberg PL, ter Bruggen JP. Rivastigmine als ondersteuning bij het dilemma van de behandeling van hallucinaties optredend bij ziekte van Parkinson [Rivastigmine as adjunctive therapy in the therapeutic dilemma for the treatment of hallucinations due to Parkinson disease]. Tijdschr Gerontol Geriatr. 2006 Jul;37(3):117-20. Dutch. PMID: 16886519.
  355. Kurita A, Ochiai Y, Kono Y, Suzuki M, Inoue K. The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson's disease. J Geriatr Psychiatry Neurol. 2003 Sep;16(3):184-8. doi: 10.1177/0891988703256054. PMID: 12967063.
  356. Fabbrini G, Barbanti P, Aurilia C, Pauletti C, Lenzi GL, Meco G. Donepezil in the treatment of hallucinations and delusions in Parkinson's disease. Neurol Sci. 2002 Apr;23(1):41-3. doi: 10.1007/s100720200022. PMID: 12111620.
  357. Bergman J, Lerner V. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease. Clin Neuropharmacol. 2002 Mar-Apr;25(2):107-10. doi: 10.1097/00002826-200203000-00009. PMID: 11981238.
  358. Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. Int J Geriatr Psychiatry. 2003 Oct;18(10):937-41. doi: 10.1002/gps.949. PMID: 14533126.
  359. Bullock R, Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. Curr Med Res Opin. 2002;18(5):258-64. doi: 10.1185/030079902125000813. PMID: 12240787.
  360. Ravina B, Putt M, Siderowf A, Farrar JT, Gillespie M, Crawley A, Fernandez HH, Trieschmann MM, Reichwein S, Simuni T. Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry. 2005 Jul;76(7):934-9. doi: 10.1136/jnnp.2004.050682. PMID: 15965198; PMCID: PMC1739697.
  361. van Mierlo TJM, Foncke EMJ, Post B, Schmand BA, Bloem BR, van Harten B, Tissingh G, Munts AG, de Haan RJ, de Bie RMA; other individuals of the CHEVAL Study Group. Rivastigmine for minor visual hallucinations in Parkinson's disease: A randomized controlled trial with 24 months follow-up. Brain Behav. 2021 Aug;11(8):e2257. doi: 10.1002/brb3.2257. Epub 2021 Jul 21. PMID: 34291590; PMCID: PMC8413762.
  362. Dubois B, Tolosa E, Katzenschlager R, Emre M, Lees AJ, Schumann G, Pourcher E, Gray J, Thomas G, Swartz J, Hsu T, Moline ML. Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study. Mov Disord. 2012 Sep 1;27(10):1230-8. doi: 10.1002/mds.25098. Epub 2012 Aug 22. PMID: 22915447.
  363. Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord. 2001 Nov;16(6):1171-4. doi: 10.1002/mds.1204. PMID: 11748755.
  364. Voon V, Fox S, Butler TR, Lang AE. Antidepressants and psychosis in Parkinson disease: a case series. Int J Geriatr Psychiatry. 2007 Jun;22(6):601-4. doi: 10.1002/gps.1764. PMID: 17450623.
  365. Meco G, Bernardi S. Antidepressant use in treatment of psychosis with comorbid depression in Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jan 30;31(1):311-3. doi: 10.1016/j.pnpbp.2006.06.016. Epub 2006 Aug 17. PMID: 16919377.
  366. Lauterbach EC. Dopaminergic hallucinosis with fluoxetine in Parkinson's disease. Am J Psychiatry. 1993 Nov;150(11):1750. doi: 10.1176/ajp.150.11.1750a. PMID: 8214188.
  367. Normann C, Hesslinger B, Frauenknecht S, Berger M, Walden J. Psychosis during chronic levodopa therapy triggered by the new antidepressive drug mirtazapine. Pharmacopsychiatry. 1997 Nov;30(6):263-5. doi: 10.1055/s-2007-979504. PMID: 9442549.
  368. Matsuda Y, Kishi T, Shibayama H, Iwata N. Yokukansan in the treatment of behavioral and psychological symptoms of dementia: a systematic review and meta-analysis of randomized controlled trials. Hum Psychopharmacol. 2013 Jan;28(1):80-6. doi: 10.1002/hup.2286. PMID: 23359469.
  369. Yu CH, Ishii R, Yu SC, Takeda M. Yokukansan and its ingredients as possible treatment options for schizophrenia. Neuropsychiatr Dis Treat. 2014 Sep 1;10:1629-34. doi: 10.2147/NDT.S67607. PMID: 25210456; PMCID: PMC4156002.
  370. Hatano T, Hattori N, Kawanabe T, Terayama Y, Suzuki N, Iwasaki Y, Fujioka T; Yokukansan Parkinson’s Disease Study Group. An exploratory study of the efficacy and safety of yokukansan for neuropsychiatric symptoms in patients with Parkinson's disease. J Neural Transm (Vienna). 2014;121(3):275-81. doi: 10.1007/s00702-013-1105-y. Epub 2013 Oct 30. PMID: 24169925.
  371. Kawanabe T, Yoritaka A, Shimura H, Oizumi H, Tanaka S, Hattori N. Successful treatment with Yokukansan for behavioral and psychological symptoms of Parkinsonian dementia. Prog Neuropsychopharmacol Biol Psychiatry. 2010 Mar 17;34(2):284-7. doi: 10.1016/j.pnpbp.2009.11.019. Epub 2009 Dec 3. PMID: 19948198.
  372. Abe K, Chiba Y, Katsuse O, Hirayasu Y. A Case of Parkinson Disease With Both Visual Hallucination and Pain Improved by Gabapentin. Clin Neuropharmacol. 2016 Jan-Feb;39(1):55-6. doi: 10.1097/WNF.0000000000000122. PMID: 26757314.
  373. Parsons KA, Derkits ME. Visual hallucinations associated with gabapentin use. Am J Health Syst Pharm. 2016 May 15;73(10):631-4. doi: 10.2146/ajhp150136. PMID: 27147215.
  374. Nishioka K, Tanaka R, Shimura H, Hirano K, Hatano T, Miyakawa K, Arai H, Hattori N, Urabe T. Quantitative evaluation of electroconvulsive therapy for Parkinson's disease with refractory psychiatric symptoms. J Neural Transm (Vienna). 2014 Nov;121(11):1405-10. doi: 10.1007/s00702-014-1212-4. Epub 2014 Apr 18. PMID: 24744048.
  375. Ueda S, Koyama K, Okubo Y. Marked improvement of psychotic symptoms after electroconvulsive therapy in Parkinson disease. J ECT. 2010 Jun;26(2):111-5. doi: 10.1097/YCT.0b013e3181c18a3d. PMID: 20386461.
  376. Kennedy R, Mittal D, O'Jile J. Electroconvulsive therapy in movement disorders: an update. J Neuropsychiatry Clin Neurosci. 2003 Fall;15(4):407-21. doi: 10.1176/jnp.15.4.407. PMID: 14627767.
  377. Usui C, Hatta K, Doi N, Kubo S, Kamigaichi R, Nakanishi A, Nakamura H, Hattori N, Arai H. Improvements in both psychosis and motor signs in Parkinson's disease, and changes in regional cerebral blood flow after electroconvulsive therapy. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Aug 15;35(7):1704-8. doi: 10.1016/j.pnpbp.2011.05.003. Epub 2011 May 12. PMID: 21605615.
  378. Takamiya A, Seki M, Kudo S, Yoshizaki T, Nakahara J, Mimura M, Kishimoto T. Electroconvulsive Therapy for Parkinson's Disease: A Systematic Review and Meta-Analysis. Mov Disord. 2021 Jan;36(1):50-58. doi: 10.1002/mds.28335. Epub 2020 Oct 14. PMID: 33280168.
  379. Calderón-Fajardo H, Cervantes-Arriaga A, Llorens-Arenas R, Ramírez-Bermudez J, Ruiz-Chow Á, Rodríguez-Violante M. Electroconvulsive therapy in Parkinson's disease. Arq Neuropsiquiatr. 2015 Oct;73(10):856-60. doi: 10.1590/0004-282X20150131. Epub 2015 Sep 1. PMID: 26331387.
  380. KIROV K, RACHEV I. Sluchai na uspeshno izlekuvane na psikhoza pri sledentsefaliten Parkinsonizum s elektroshok [Case of successful electroshock therapy of psychosis in postencephalitis parkinsonism]. Suvr Med (Sofiia). 1956;7(5):89-93. Bulgarian. PMID: 13391605.
  381. Hurwitz TA, Calne DB, Waterman K. Treatment of dopaminomimetic psychosis in Parkinson's disease with electroconvulsive therapy. Can J Neurol Sci. 1988 Feb;15(1):32-4. doi: 10.1017/s0317167100027141. PMID: 3345460.
  382. Höflich G, Burghof KW, Kasper S, Möller HJ. Elektrokrampftherapie bei Komorbidität einer therapieresistenten paranoid-halluzinatorischen Psychose mit Morbus Parkinson [Electroconvulsive therapy in comorbidity of treatment refractory paranoid hallucinatory psychoses with Parkinson disease]. Nervenarzt. 1994 Mar;65(3):202-5. German. PMID: 7909917.
  383. Factor SA, Molho ES, Brown DL. Combined clozapine and electroconvulsive therapy for the treatment of drug-induced psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 1995 Summer;7(3):304-7. doi: 10.1176/jnp.7.3.304. PMID: 7580188.
  384. Ozer F, Meral H, Aydin B, Hanoglu L, Aydemir T, Oral T. Electroconvulsive therapy in drug-induced psychiatric states and neuroleptic malignant syndrome. J ECT. 2005 Jun;21(2):125-7. doi: 10.1097/01.yct.0000159325.08303.45. PMID: 15905757.
  385. Hanin B, Lerner Y, Srour N. An unusual effect of ECT on drug-induced parkinsonism and tardive dystonia. Convuls Ther. 1995 Dec;11(4):271-4. PMID: 8919580.
  386. Herzog J, Volkmann J, Krack P, Kopper F, Pötter M, Lorenz D, Steinbach M, Klebe S, Hamel W, Schrader B, Weinert D, Müller D, Mehdorn HM, Deuschl G. Two-year follow-up of subthalamic deep brain stimulation in Parkinson's disease. Mov Disord. 2003 Nov;18(11):1332-7. doi: 10.1002/mds.10518. PMID: 14639676.
  387. Castelli L, Perozzo P, Zibetti M, Crivelli B, Morabito U, Lanotte M, Cossa F, Bergamasco B, Lopiano L. Chronic deep brain stimulation of the subthalamic nucleus for Parkinson's disease: effects on cognition, mood, anxiety and personality traits. Eur Neurol. 2006;55(3):136-44. doi: 10.1159/000093213. Epub 2006 May 8. PMID: 16682797.
  388. Vesper J, Haak S, Ostertag C, Nikkhah G. Subthalamic nucleus deep brain stimulation in elderly patients--analysis of outcome and complications. BMC Neurol. 2007 Mar 16;7:7. doi: 10.1186/1471-2377-7-7. PMID: 17367531; PMCID: PMC1847528.
  389. Hanna S, Palmadottir V, Penar PL, Boyd JT. Pallidal stimulation-induced psychosis and suicidality in Parkinson's disease. Clin Park Relat Disord. 2022 Dec 17;8:100175. doi: 10.1016/j.prdoa.2022.100175. PMID: 36594072; PMCID: PMC9803938.
  390. Segal GS, Xie SJ, Paracha SU, Grossberg GT. Psychosis in Parkinson's Disease: Current Treatment Options and Impact on Patients and Caregivers. J Geriatr Psychiatry Neurol. 2021 Jul;34(4):274-279. doi: 10.1177/08919887211018280. PMID: 34219522.
  391. Diederich NJ, Pieri V, Goetz CG. Coping strategies for visual hallucinations in Parkinson's disease. Mov Disord. 2003 Jul;18(7):831-2. doi: 10.1002/mds.10450. PMID: 12815665.
  392. McGorry PD. Psychoeducation in first-episode psychosis: a therapeutic process. Psychiatry. 1995 Nov;58(4):313-28. doi: 10.1080/00332747.1995.11024736. PMID: 8746490.
  393. Tarrier N, Wykes T. Is there evidence that cognitive behaviour therapy is an effective treatment for schizophrenia? A cautious or cautionary tale? Behav Res Ther. 2004 Dec;42(12):1377-401. doi: 10.1016/j.brat.2004.06.020. PMID: 15500811.
  394. Jenner JA, van de Willige G, Wiersma D. Effectiveness of cognitive therapy with coping training for persistent auditory hallucinations: a retrospective study of attenders of a psychiatric out-patient department. Acta Psychiatr Scand. 1998 Nov;98(5):384-9. doi: 10.1111/j.1600-0447.1998.tb10103.x. PMID: 9845177.
  395. Goetz CG, Vogel C, Tanner CM, Stebbins GT. Early dopaminergic drug-induced hallucinations in parkinsonian patients. Neurology. 1998 Sep;51(3):811-4. doi: 10.1212/wnl.51.3.811. PMID: 9748031.
  396. Gordon PC, Kauark RB, Costa CD, de Oliveira MO, Godinho FL, Rocha MS. Clinical Implications of the National Institute of Neurological Disorders and Stroke Criteria for Diagnosing Psychosis in Parkinson's Disease. J Neuropsychiatry Clin Neurosci. 2016 Winter;28(1):26-31. doi: 10.1176/appi.neuropsych.15050119. Epub 2015 Oct 9. PMID: 26449268.
  397.  

Figures:

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?